0001437749-24-006037 | 10-K | XBRL Viewer

Inventory and Other Deferred Costs Disclosure [Text Block]

3. Inventory and Other Deferred Costs

Inventory and other deferred costs consists of the following:

	December 31, 2023		December 31, 2022
	(in thousands)
Raw materials	$	18,333	$	14,929
Work-in-process		2,869		3,662
Finished products		31,131		26,688
Other deferred costs		5,747		4,992

Total inventory and other deferred costs	$	58,080	$	50,271

We had inventory on consignment at customer sites of $2.0 million and $1.5 million at December 31, 2023 and 2022, respectively.

In connection with our RestoreFlow allograft business, other deferred costs include costs incurred for the preservation of human tissues available for shipment, tissues currently in active processing, and tissues held in quarantine pending release to implantable status. By federal law, human tissues cannot be bought or sold. Therefore, the tissues we preserve are not held as inventory, and the costs we incur to procure and process vascular tissues are instead accumulated and deferred. These costs include fixed and variable overhead costs associated with the cryopreservation process, including primarily direct labor costs, tissue recovery fees, inbound freight charges, indirect materials and facilities costs. General and administrative expenses and selling expenses associated with the provision of these services are expensed as incurred.

Note 4 - Property and Equipment - Depreciation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Depreciation expense	$ 3,423	$ 3,250	$ 3,280

Note 5 - Goodwill and Other Intangibles - Schedule of Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Balance	$ 65,945	$ 65,945
Additions for acquisitions	0	0
Purchase accounting adjustments	0	0
Effects of currency exchange	0	0
Balance	$ 65,945	$ 65,945

Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

Basis of Accounting, Policy [Policy Text Block]

Note 10 - Stockholders' Equity - Summary of Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Outstanding (in shares)	859,975	846,754	931,840
Outstanding, weighted average exercise price (in dollars per share)	$ 37.53	$ 33.83	$ 28.22
Outstanding, weighted average contractual term (Year)	4 years 5 months 1 day	4 years 4 months 6 days	4 years 6 months	4 years 5 months 26 days
Outstanding, aggregate intrinsic value	$ 10,924	$ 7,878	$ 13,888	$ 11,442
Granted (in shares)	148,115	159,275	151,161
Granted, weighted average exercise price (in dollars per share)	$ 54.71	$ 47.21	$ 48.6
Exercised (in shares)	(207,643)	(133,963)	(217,121)
Exercised, weighted average exercise price (in dollars per share)	$ 29.72	$ 25.8	$ 20.95
Exercised, aggregate intrinsic value	$ 5,914	$ 3,021	$ 6,975
Canceled / Expired (in shares)	(19,323)	(12,091)	(19,126)
Canceled / Expired (in dollars per share)	$ 41.55	$ 35.53	$ 23.18
Outstanding (in shares)	781,124	859,975	846,754	931,840
Outstanding, weighted average exercise price (in dollars per share)	$ 42.78	$ 37.53	$ 33.83	$ 28.22
Exercisable (in shares)	356,519	369,593	301,692
Exercisable, weighted average exercise price (in dollars per share)	$ 36.83	$ 32.16	$ 27.4
Exercisable, weighted average contractual term (Year)	3 years 2 months 15 days	3 years 2 months 1 day	3 years 3 months 18 days
Exercisable, aggregate intrinsic value	$ 7,107	$ 5,223	$ 6,886
Expected to vest (in shares)	424,605	490,382	545,062
Expected to vest, weighted average exercise price (in dollars per share)	$ 47.78	$ 41.59	$ 37.38
Expected to vest, weighted average contractual term (Year)	5 years 5 months 4 days	5 years 2 months 23 days	5 years 1 month 28 days

Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2023

Accounting Policies [Abstract]

Description of Business

Unless the context requires otherwise, references to LeMaitre, LeMaitre Vascular, we, our, and us refer to LeMaitre Vascular, Inc. and our subsidiaries. We develop, manufacture, and market medical devices and implants used primarily in the field of vascular surgery. We also derive revenues from the processing and cryopreservation of human tissues for implantation in patients. We operate in a single segment in which our principal product lines include the following: anastomotic clips, biologic vascular and dialysis grafts, biologic vascular and cardiac patches, carotid shunts, embolectomy catheters, occlusion catheters, radiopaque marking tape, synthetic vascular grafts, and valvulotomes. Our offices and production facilities are located in Burlington, Massachusetts; Fox River Grove, Illinois; North Brunswick, New Jersey; Chandler, Arizona; Vaughan, Canada; Sulzbach, Germany; Milan, Italy; Madrid, Spain; Hereford, England; Dublin, Ireland; Kensington, Australia; Tokyo, Japan; Shanghai, China; Singapore; Seoul, Korea; and Bangkok, Thailand.

Consolidation, Policy [Policy Text Block]

Consolidation and Basis of Presentation

Our consolidated financial statements include the accounts of LeMaitre Vascular and the accounts of our wholly-owned subsidiaries, LeMaitre Vascular GmbH, LeMaitre Vascular GK, Vascutech Acquisition LLC, LeMaitre Acquisition LLC, LeMaitre Vascular SAS, LeMaitre Vascular S.r.l., LeMaitre Vascular Spain S.L, LeMaitre Vascular Switzerland GmbH, LeMaitre Vascular ULC, LeMaitre Vascular AS, LeMaitre Vascular Pty Ltd, Bio Nova International Pty Ltd, Bio Nova Holdings Pty Ltd, LeMaitre Vascular, Ltd., LeMaitre Medical Technology (Shanghai) Co. Ltd, LeMaitre Cardial SAS, LeMaitre Pte Ltd, LeMaitre Ltd, and LeMaitre Co., Ltd. All significant intercompany accounts and transactions have been eliminated in consolidation.

Foreign Currency Transactions and Translations Policy [Policy Text Block]

Foreign Currency Translation

Balance sheet accounts of foreign subsidiaries are translated into U.S. dollars at year-end exchange rates. Operating accounts are translated at average exchange rates for each year. Net translation gains or losses are adjusted directly to a separate component of other comprehensive income (loss) within stockholders’ equity. Foreign exchange transaction gains (losses), substantially all of which relate to intercompany activity between us and our foreign subsidiaries, are included in other income (expense) in the accompanying consolidated statements of operations.

Use of Estimates, Policy [Policy Text Block]

Estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. The Company is not aware of any specific event or circumstance that would require an update to its accounting estimates or adjustments to the carrying value of its assets and liabilities. Our estimates and assumptions, including those related to bad debts, inventories, intangible assets, sales returns and discounts, share-based compensation, and income taxes, are reviewed on an ongoing basis and updated as appropriate. Actual results could differ from those estimates.

Revenue from Contract with Customer [Policy Text Block]

Revenue Recognition

Our revenue is derived primarily from the sale of disposable or implantable devices used during vascular surgery. We sell primarily directly to hospitals and to a lesser extent to international distributors, as described below, and, during the periods presented in our consolidated financial statements, entered into consigned inventory arrangements with either hospitals or distributors on a limited basis. We also derive revenues from the processing and cryopreservation of human tissues for implantation in patients. These revenues are recognized when services have been provided and the tissue has been shipped to the customer, provided all other revenue recognition criteria discussed in the succeeding paragraph have been met.

We record revenue under the provisions of ASU 2014-09, Revenue from Contracts with Customers (Topic 606). The core principle of Topic 606 is that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard explains that to achieve the core principle, an entity should take the following actions:

Step 1: Identify the contract with a customer

Step 2: Identify the performance obligations in the contract

Step 3: Determine the transaction price

Step 4: Allocate the transaction price to the performance obligations

Step 5: Recognize revenue when or as the entity satisfies a performance obligation

Revenue is recognized when or as a company satisfies a performance obligation by transferring a promised good or service to a customer (which is when the customer obtains control of that good or service). In instances in which shipping and handling activities are performed after a customer takes control of the goods (such as when title passes upon shipment from our dock), we have made the policy election allowed under Topic 606 to account for these activities as fulfillment costs and not as performance obligations.

We generally reference customer purchase orders to determine the existence of a contract. Orders that are not accompanied by a purchase order are confirmed with the customer either in writing or verbally. The purchase orders or similar correspondence, once accepted, identify the performance obligations as well as the transaction price, and otherwise outline the rights and obligations of each party. We allocate the transaction price of each contract among the performance obligations in accordance with the pricing of each item specified on the purchase order, which is in turn based on standalone selling prices per our published price lists. In cases where we discount products or provide certain items free of charge, we allocate the discount proportionately to all performance obligations, unless it can be demonstrated that the discount should be allocated entirely to one or more, but not all, of the performance obligations.

We record revenue, net of allowances for returns and discounts, fees paid to group purchasing organizations, and any sales and value added taxes required to be invoiced, which we have elected to exclude from the measurement of the transaction price as allowed by the standard, at the time of shipment (taking into consideration contractual shipping terms), or in the case of consigned inventory, when it is consumed. Shipment is the point at which control of the product and title passes to our customers, and at which LeMaitre has a present right to receive payment for the goods.

Below is a disaggregation of our revenue by major geographic area, which is among the primary categorizations used by management in evaluating financial performance, for the periods indicated (in thousands):

	Year ended December 31,
	2023		2022		2021
Americas	$	130,308	$	109,439	$	102,265
Europe, Middle East and Africa		51,099		41,854		42,132
Asia Pacific		12,077		10,358		10,027
Total	$	193,484	$	161,651	$	154,424

We do not carry any contract assets or contract liabilities, as there are generally no unbilled amounts due from customers under contracts for which we have partially satisfied performance obligations, or amounts received from customers for which we have not satisfied performance obligations. We satisfy our performance obligations under revenue contracts within a very short time period from receipt of the orders, and payments from customers are typically received within 30 to 60 days of fulfillment of the orders, except in certain geographies such as Italy, Spain and France where the payment cycle is customarily longer. Accordingly, there is no significant financing component to our revenue contracts. Additionally, we have elected as a policy that incremental costs (such as commissions) incurred to obtain contracts are expensed as incurred, due to the short-term nature of the contracts.

Customers returning products may be entitled to full or partial credit based on the condition and timing of the return. To be accepted, a returned product must be unopened (if sterile), unadulterated, and undamaged, must have at least 18 months remaining prior to its expiration date, or twelve months for our hospital customers in Europe, and generally be returned within 30 days of shipment. These return policies apply to sales to both hospitals and distributors. The amount of products returned to us, either for exchange or credit, has not been material. Nevertheless, we provide for an allowance for future sales returns based on historical returns experience, which requires judgment. Our cost of replacing defective products has not been material and is accounted for at the time of replacement.

Research and Development Expense, Policy [Policy Text Block]

Research and Development Expense

Research and development costs, principally salaries, laboratory testing, and supplies, are expensed as incurred and also include royalty payments associated with licensed and acquired intellectual property.

Shipping and Handling [Policy Text Block]

Shipping and Handling Costs

Shipping and handling fees paid by customers are recorded within net sales, with the related expense recorded in cost of sales.

Advertising Cost [Policy Text Block]

Advertising Costs

Advertising costs are expensed as incurred and are included as a component of sales and marketing expense in the accompanying consolidated statements of operations. Advertising costs are as follows:

	Year ended December 31,
	2023		2022		2021
			(in thousands)

Advertising expense	$	240	$	195	$	236

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash and Cash Equivalents

We consider all highly liquid instruments purchased with maturity dates of 90 days or less to be cash equivalents. Cash and cash equivalents are primarily invested in money market funds. These amounts are stated at cost, which approximates fair value.

Marketable Securities, Policy [Policy Text Block]

Short-term Marketable Securities

Our short-term marketable securities are available-for-sale securities carried at fair value, with unrealized gains and losses recorded in other comprehensive income. They include a managed income mutual fund investing mainly in short-term investment-grade, U.S. dollar denominated fixed and floating rate debt, and a short-duration bond fund.

Concentration Risk, Credit Risk, Policy [Policy Text Block]

Concentrations of Credit Risk

Our financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. Cash equivalents represent highly liquid investments with maturities of 90 days or less at the date of purchase. Credit risk related to cash and cash equivalents are limited based on the creditworthiness of the financial institutions at which these funds are held. We maintain cash balances in several banks. Accounts located in the U.S. are insured by the Federal Deposit Insurance Corporation (FDIC) up to $250,000. Certain of our account balances exceed the FDIC limit. Cash balances held outside the U.S. totaled approximately $10.0 million as of December 31, 2023.

Our accounts receivable are with customers based in the U.S. and internationally. Accounts receivable generally are due within 30 to 60 days of invoice and are stated at amounts due from customers, net of an allowance for credit losses and sales returns, other than in certain European markets where the payment cycle is customarily longer. We perform ongoing credit evaluations of the financial condition of our customers and adjust credit limits based upon payment history and the current creditworthiness of the customers, as determined by a review of their current credit information. We continuously monitor aging reports, collections, and payments from customers, and maintain a provision for estimated credit losses based upon historical experience and any specific customer collection issues we identify.

We closely monitor outstanding receivables for potential collection risks, including those that may arise from economic conditions, in both the U.S. and international economies. Our European sales to government-owned or supported customers such as hospitals, distributors and agents, particularly in Italy, Spain and France, may be subject to significant payment delays due to government austerity measures impacting funding and payment practices. As of December 31, 2023 our receivables in Italy, Spain and France totaled $1.1 million, $1.0 million and $1.2 million, respectively. Receivables balances with certain government-owned hospitals and government-supported customers in these countries can accumulate over a period of time and then subsequently be settled as lump sum payments. While we believe our allowance for credit losses in these countries is adequate as of December 31, 2023, if significant changes were to occur in the payment practices of these European governments or if government funding becomes unavailable, we may not be able to collect on receivables due to us from these customers and our write offs of uncollectible amounts may increase.

We write off accounts receivable when they become uncollectible. Such credit losses have historically been within our expectations and allowances. The allowance for credit losses is our best estimate of the amount of probable credit losses in our existing accounts receivable. We review our allowance for credit losses on a monthly basis and all past due balances are reviewed individually for collectability. The provision for the allowance for credit losses is recorded in general and administrative expenses. The following is a summary of our allowance for credit losses and sales returns:

	Balance at		Additions		Deductions		Balance at
	Beginning		(recoveries) charged		from		End of
	of Period		to Income		Reserves		Period
	(in thousands)
Allowance for credit losses and sales returns:
Year ended December 31, 2023	$	835	$	344	$	238	$	941
Year ended December 31, 2022		679		637		481		835
Year ended December 31, 2021		623		263		207		679

Fair Value of Financial Instruments, Policy [Policy Text Block]

Fair Value of Financial Instruments

Our financial instruments include cash and cash equivalents, short-term marketable securities, accounts receivable and trade payables. The fair value of these instruments approximates their carrying value based upon their short-term nature or variable rates of interest. Unrealized gains and losses on our short-term marketable securities are recorded in other comprehensive income. As of December 31, 2023 and 2022, our short-term marketable securities reflected an unrealized loss of $1.2 million and $1.8 million, respectively, as a result of increasing market interest rates.

Inventory and Other Deferred Costs [Policy Text Block]

Inventory and Other Deferred Costs

Inventory and Other Deferred Costs consists of finished products, work-in-process, raw materials and costs deferred in connection with human tissue cryopreservation services of our RestoreFlow allograft business. We value inventory and other deferred costs at the lower of cost or market value. Cost includes materials, labor and manufacturing overhead and is determined using the first-in, first-out (FIFO) method. On a quarterly basis, we review inventory quantities on hand and analyze the provision for excess and obsolete inventory based primarily on product expiration dating and our estimated sales forecast, which is based on sales history and anticipated future demand. Our estimates of future product demand may not be accurate, and we may understate or overstate the provision required for excess and obsolete inventory. Accordingly, any significant unanticipated changes in demand could have a significant impact on the value of our inventory and results of operations.

Research, Development, and Computer Software, Policy [Policy Text Block]

Cloud Computing Arrangements

The Company capitalizes qualifying set-up and implementation costs related to the Company’s cloud computing arrangements. The deferred costs are amortized over the term of the associated cloud computing arrangement on a straight-line basis which is representative of the pattern in which the Company expects to benefit from access to the cloud computing arrangement.

Capitalized cloud computing implementation costs are presented in prepaid expenses and other current assets and other assets on the consolidated balance sheet. As of December 31, 2023, the Company had net capitalized cloud computing implementation costs of $3.6 million.

Property, Plant and Equipment, Policy [Policy Text Block]

Property and Equipment

Property and equipment are recorded at cost. Depreciation is provided over the estimated useful lives of the related assets using straight-line method as follows:

Description	Useful Life (in years)
Computer hardware	3	–	5
Machinery and equipment	3	–	10
Building and leasehold improvements	The shorter of its useful life or lease term

Expenditures for maintenance and repairs are charged to operations when incurred, while additions and betterments are capitalized. When assets are retired or disposed, the asset’s original cost and related accumulated depreciation are eliminated from the accounts and any gain or loss is reflected in the statement of operations.

Business Combinations Policy [Policy Text Block]

Valuation of Business Combinations

We assign the value of the consideration transferred to acquire a business to the tangible assets and identifiable intangible assets acquired and liabilities assumed on the basis of their fair values at the date of acquisition. We assess the fair value of assets, including intangible assets, using a variety of methods and are usually performed by an independent appraiser who measures fair value from the perspective of a market participant.

Acquisitions have been accounted for using the acquisition method, and the acquired companies’ results have been included in the accompanying consolidated financial statements from their respective dates of acquisition. Acquisition transaction costs have been recorded in general and administrative expenses, and are expensed as incurred. Allocation of the purchase price for acquisitions is based on estimates of the fair value of the net assets acquired and is subject to adjustment upon finalization of the purchase price allocation.

Our acquisitions have historically been made at prices above the fair value of the acquired assets, resulting in goodwill, due to expectations of synergies of combining the businesses. These synergies include use of our existing commercial infrastructure to expand sales of the acquired businesses’ products, use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of our products, and the elimination of redundant facilities, functions and staffing.

Contingent Consideration [Policy Text Block]

Contingent Consideration

Contingent consideration for acquisitions is recognized at the date of acquisition, based on the fair value at that date, and then re-measured periodically through adjustments to net income.

Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]

Impairment of Long-lived Assets

We review our long-lived assets (primarily property and equipment and intangible assets) subject to amortization quarterly to determine if any adverse conditions exist or a change in circumstances has occurred that would indicate impairment or a change in the remaining useful life. Conditions that may indicate impairment include, but are not limited to, a significant adverse change in legal factors or business climate that could affect the value of an asset, a product recall, or an adverse action or assessment by a regulator. If an impairment indicator exists, we test the intangible asset for recoverability. We record impairment losses on long-lived assets used in operations when events and circumstances indicate that the assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amount of those assets. Impairment is measured based on the fair market value of the affected asset using discounted cash flows.

Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]

Goodwill

Goodwill represents the amount of consideration paid in connection with business acquisitions in excess of the fair value of assets acquired and liabilities assumed. Goodwill is evaluated for impairment annually, or more frequently if indicators of impairment are present or changes in circumstances suggest that an impairment may exist. We evaluate the December 31 balance of the carrying value of goodwill based on a single reporting unit annually. We perform an assessment of qualitative factors to determine if it is “more likely than not” that the fair value of our reporting unit is less than its carrying value as a basis for determining whether it is necessary to perform the quantitative goodwill impairment test. The “more likely than not” threshold is defined as having a likelihood of more than 50 percent. The quantitative goodwill impairment test compares the fair value of a reporting unit with its carrying amount, including goodwill. If the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired. If the carrying amount of a reporting unit exceeds its fair value, an impairment loss is recognized in an amount equal to that excess, limited to the total amount of goodwill allocated to that reporting unit. We have determined that no goodwill impairment charges were required for the years ended December 31, 2023, 2022 or 2021.

Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]

Other Intangible Assets

Other intangible assets consist primarily of patents, trademarks, technology licenses, and customer relationships acquired in connection with business acquisitions and asset acquisitions and are amortized over their estimated useful lives, ranging from 2 to 16 years.

Share-Based Payment Arrangement [Policy Text Block]

Stock-based Compensation

We recognize, as expense, the estimated fair value of stock options to employees determined using the Black-Scholes option pricing model. Share-based compensation charges are recorded across the consolidated statement of operations based upon the grantee’s primary function. We have elected to recognize the compensation cost of all share-based awards on a straight-line basis over the vesting period of the award. In periods that we grant stock options, fair value assumptions are based on volatility, interest, dividend yield, and expected term over which the stock options will be outstanding. The computation of expected volatility is based on the historical volatility of the company’s stock. The interest rate for periods within the contractual life of the award is based on the U.S. Treasury risk-free interest rate in effect at the time of grant. Historical data on exercise patterns is the basis for estimating the expected life of an option. The expected annual dividend rate was calculated by dividing our annual dividend, based on the most recent quarterly dividend rate, by the closing stock price on the grant date.

We also issue restricted stock units (RSUs) and performance-based restricted stock units (PSUs) as additional forms of equity compensation to our employees, officers, and directors, pursuant to our stockholder-approved 2006 Plan. RSUs entitle the grantee to an issuance of stock at no cost and generally vest over a period of time determined by our Board of Directors at the time of grant. PSUs granted in December 2022 vested based on achievement of operating income for 2023 against budgeted operating income as approved by our Board of Directors. The fair market value of the award is determined based on the number of RSUs and PSUs granted and the market value of our common stock on the grant date and is amortized to expense over the period of vesting. Unvested RSUs and PSUs are forfeited and canceled as of the date that employment or service to the company terminates. RSUs and PSUs are settled in shares of our common stock upon vesting. We typically repurchase common stock upon our employees’ vesting in RSUs and PSUs in order to cover any minimum tax withholding liability as a result of the awards having vested. PSUs granted in December 2022 based on achievement of operating income for 2023 against budgeted operating income as approved by our Board of Directors were achieved and therefore awarded to the recipients.

Commitments and Contingencies, Policy [Policy Text Block]

Commitments and Contingencies

In the normal course of business, we are subject to proceedings, lawsuits, and other claims and assessments for matters related to, among other things, patent infringement, business acquisitions, employment, commercial matters and product recalls. We assess the likelihood of any adverse judgments or outcomes to these matters as well as potential ranges of probable losses. A determination of the amount of reserves required, if any, for these contingencies is made after careful analysis of each individual issue. The required reserves may change in the future due to new developments or changes in approach, such as a change in settlement strategy in dealing with each matter. We record charges for anticipated losses in connection with litigation and claims against us when we conclude a loss is probable and we can reasonably estimate the loss. Legal costs associated with loss contingencies are expensed as incurred. During the years ended December 31, 2023, 2022 and 2021, we were not subject to any material litigation or claims and assessments.

Sales of medical devices outside the U.S. are subject to international regulatory requirements that vary from country to country. These requirements and the amount of time required for approval may differ from our experiences with the U.S. FDA. In the EU we are required to obtain CE marks for our products, which denote conformity to essential requirements for manufacturers of higher-risk devices. Failure to obtain, retain or maintain these CE marks would impact our ability to sell our products in certain European countries and could cause our business to suffer.

Income Tax, Policy [Policy Text Block]

Income Taxes

We account for income taxes under the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred taxes are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. The provision for income taxes includes taxes currently payable and deferred taxes resulting from the tax effects of temporary differences between the financial statement and tax bases of assets and liabilities. We maintain valuation allowances where it is more likely than not that all or a portion of a deferred tax asset will not be realized. Changes in the valuation allowances are included in our tax provision in the period of change. In determining whether a valuation allowance is warranted, we evaluate factors such as prior earnings history, expected future earnings, carry-back and carry-forward periods and tax strategies that could potentially enhance the likelihood of the realization of a deferred tax asset.

We recognize, measure, present and disclose in our financial statements, uncertain tax positions that we have taken or expect to take on a tax return. We recognize in our financial statements the impact of tax positions that meet a “more likely than not” threshold, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement.

Our policy is to classify interest and penalties related to unrecognized tax benefits as income tax expense.

Comprehensive Income, Policy [Policy Text Block]

Comprehensive Income

Comprehensive income is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Other than reported net income, comprehensive income includes foreign currency translation adjustments and unrealized gains and losses on our marketable securities, which are disclosed in the accompanying consolidated statements of comprehensive income. There were no reclassifications out of comprehensive income for the years ended December 31, 2023, 2022 or 2021.

Accumulated other comprehensive loss consisted of foreign currency translation adjustment losses of $3.4 million and $4.2 million as of December 31, 2023 and 2022, respectively, and unrealized losses on short-term marketable securities of $1.2 million and $1.8 million as of December 31, 2023 and 2022, respectively.

Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]

Restructuring

We record restructuring charges incurred in connection with consolidation or relocation of operations, exited business lines, reductions in force, or distributor terminations. These restructuring charges, which reflect our commitment to a termination or exit plan, are based on estimates of the expected costs associated with site closure, legal matters, contract terminations, severance payments, or other costs directly related to the restructuring. If the actual cost incurred exceeds the estimated cost, an additional charge to earnings will result. If the actual cost is less than the estimated cost, a credit to earnings will be recognized.

Earnings Per Share, Policy [Policy Text Block]

Earnings per Share

We compute basic earnings per share by dividing net income available for common stockholders by the weighted average number of shares outstanding during the year. Except where the result would be anti-dilutive to net income per share, diluted earnings per share has been computed using the treasury stock method and reflects the potential vesting of restricted common stock and the potential exercise of stock options, as well as their related income tax effects.

The computation of basic and diluted net income per share is as follows:

		Year ended December 31,
	2023		2022		2021
		(in thousands, except per share data)
Basic:
Net income available for common stockholders	$	30,105	$	20,636	$	26,907

Weighted average shares outstanding		22,217		21,975		21,157

Basic earnings per share	$	1.36	$	0.94	$	1.27

Diluted:
Net income available for common stockholders	$	30,105	$	20,636	$	26,907

Weighted-average shares outstanding		22,217		21,975		21,157
Common stock equivalents, if dilutive		206		196		318

Shares used in computing diluted earnings per common share		22,423		22,171		21,475

Diluted earnings per share	$	1.34	$	0.93	$	1.25

Shares excluded in computing diluted earnings per share as those shares would be anti-dilutive		295		293		10

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies and are generally adopted by the Company as of the specified effective date.

Not Yet Effective

In December 2023 the FASB issued ASU 2023-09, Income Taxes Topic 740 - Improvements to Income Tax Disclosures. This amendment is expected to enhance the transparency and decision usefulness of income tax disclosures by requiring public business entities, on an annual basis, to disclose specific categories in the rate reconciliation, additional information for reconciling items that meet a quantitative threshold and certain information about income taxes paid. This revised guidance is effective for financial statements issued for fiscal years beginning after December 15, 2024. We are currently evaluating the impacts of the new standard.

In November 2023 the FASB issued ASU 2023-07, Segment Reporting Topic 280- Improvements to Reportable Segment Disclosures. This amendment requires disclosure of incremental segment information on an annual and interim basis. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, and requires retrospective application to all prior periods presented in the financial statements. We are currently evaluating the impacts of the new standard.

Note 9 - Income Taxes (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2023	Dec. 31, 2020
Unrecognized Tax Benefits	$ 612	$ 768	$ 587	$ 820
Deferred Tax Assets, Valuation Allowance, Total	1,628		1,702
Deferred Tax Assets, Operating Loss Carryforwards	1,027		942
Deferred Tax Assets, Capital Loss Carryforwards	462		462
Foreign Tax Authority [Member] \| AUSTRALIA
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	$ (100)	$ 100
Deferred Tax Assets, Operating Loss Carryforwards			1,200
Deferred Tax Assets, Capital Loss Carryforwards			1,500
Foreign Tax Authority [Member] \| FRANCE
Deferred Tax Assets, Operating Loss Carryforwards			1,700
Foreign Tax Authority [Member] \| SPAIN
Deferred Tax Assets, Operating Loss Carryforwards			500
Foreign Tax Authority [Member] \| NORWAY
Deferred Tax Assets, Operating Loss Carryforwards			100
Foreign Tax Authority [Member] \| CHINA
Deferred Tax Assets, Operating Loss Carryforwards			400
State and Local Jurisdiction [Member]
Tax Credit Carryforward, Amount			$ 1,700

Note 10 - Stockholders' Equity - Weighted Average Assumptions (Details) - Share-Based Payment Arrangement, Option [Member] - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Dividend yield	1.02%	1.06%	0.91%
Volatility	43.00%	44.60%	46.00%
Risk-free interest rate	4.30%	3.90%	1.10%
Weighted average expected option term (in years) (Year)	4 years 6 months	4 years 6 months	4 years 7 months 6 days
Weighted average fair value per share of options granted (in dollars per share)	$ 20.75	$ 18.1	$ 17.64

Note 6 - Revolving Line of Credit and Long-term Debt (Details Textual) - Senior Secured Credit Facility [Member] - USD ($) $ in Millions		12 Months Ended
	Jun. 22, 2020	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument, Face Amount	$ 65.0
Debt Issuance Costs, Net	1.8
Debt Instrument, Interest Rate, Effective Percentage		4.20%
Term Loan [Member]
Debt Instrument, Face Amount	$ 40.0
Debt Instrument, Term	5 years
Repayments of Long-Term Debt		$ 1.0	$ 1.0
Interest Paid, Including Capitalized Interest, Operating and Investing Activities, Total		$ 0.9
Term Loan [Member] \| Base Rate [Member] \| Minimum [Member]
Debt Instrument, Basis Spread on Variable Rate	1.25%
Term Loan [Member] \| Base Rate [Member] \| Maximum [Member]
Debt Instrument, Basis Spread on Variable Rate	1.75%
Term Loan [Member] \| Eurodollar [Member] \| Minimum [Member]
Debt Instrument, Basis Spread on Variable Rate	2.25%
Term Loan [Member] \| Eurodollar [Member] \| Maximum [Member]
Debt Instrument, Basis Spread on Variable Rate	2.75%
Term Loan [Member] \| Fed Funds Effective Rate Overnight Index Swap Rate [Member]
Debt Instrument, Basis Spread on Variable Rate	0.50%
Interest Paid, Including Capitalized Interest, Operating and Investing Activities, Total			$ 0.9
Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity	$ 25.0
Revolving Credit Facility [Member] \| Other Assets [Member]
Debt Issuance Costs, Line of Credit Arrangements, Net	$ 0.7

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 24,269	$ 19,134
Short-term marketable securities	80,805	63,557
Accounts receivable, net of allowances of $941 at December 31, 2023 and $835 at December 31, 2022	25,064	22,040
Inventory and other deferred costs	58,080	50,271
Prepaid expenses and other current assets	6,380	6,731
Total current assets	194,598	161,733
Property and equipment, net	21,754	17,901
Right-of-use leased assets	18,027	15,634
Goodwill	65,945	65,945
Other intangibles, net	41,711	46,527
Deferred tax assets	1,003	1,745
Other assets	3,740	991
Total assets	346,778	310,476
Current liabilities:
Accounts payable	3,734	2,903
Accrued expenses	23,650	19,967
Acquisition-related obligations	24	573
Lease liabilities - short-term	2,471	1,886
Total current liabilities	29,879	25,329
Lease liabilities - long-term	16,624	14,710
Deferred tax liabilities	107	69
Other long-term liabilities	2,268	2,167
Total liabilities	48,878	42,275
Stockholders’ equity:
Preferred stock, $0.01 par value; authorized 3,000,000 shares; none outstanding	0	0
Common stock, $0.01 par value; authorized 37,000,000 shares; issued 23,655,716 shares at December 31, 2022, and 23,477,784 shares at December 31, 2021	239	237
Additional paid-in capital	200,755	189,268
Retained earnings	115,430	97,773
Accumulated other comprehensive loss	(4,625)	(6,031)
Treasury stock, at cost; 1,568,595 shares at December 31, 2022 and 1,554,905 shares at December 31, 2021	(13,899)	(13,046)
Total stockholders’ equity	297,900	268,201
Total liabilities and stockholders’ equity	$ 346,778	$ 310,476

Note 9 - Income Taxes - The Provision (Benefit) for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Current:
Federal	$ 6,203	$ 5,063	$ 5,024
State	1,300	938	990
Foreign	1,084	1,035	1,287
Current Income Tax Expense (Benefit)	8,587	7,036	7,301
Deferred:
Federal	616	(144)	63
State	122	(83)	(9)
Foreign	45	45	25
Deferred Income Tax Expense (Benefit)	783	(182)	79
Provision for income taxes	$ 9,370	$ 6,854	$ 7,380

Note 1 - Significant Accounting Policies and Related Matters - Allowance for Doubtful Accounts and Sales Returns (Details) - Allowance for Doubtful Accounts and Sales Returns [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Year ended December 31, 2023	$ 835	$ 679	$ 623
Year ended December 31, 2023	344	637	263
Deductions from Reserves	238	481	207
Year ended December 31, 2023	$ 941	$ 835	$ 679

Note 14 - Accumulated Other Comprehensive Income (Loss) - Schedule of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Balance	$ 268,201	$ 254,151	$ 172,572
Balance	297,900	268,201	254,151
AOCI Attributable to Parent [Member]
Balance	(6,031)	(3,435)	(1,525)
Other comprehensive income (loss) before reclassifications	1,406		(1,910)
Amounts reclassified from accumulated other comprehensive loss	0	0	0
Balance	$ (4,625)	$ (6,031)	$ (3,435)

Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-12

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(19))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(6))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2

Note 7 - Accrued Expenses and Other Long-term Liabilities - Other Long-term Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Acquisition-related liabilities	$ 1,406	$ 1,354
Income taxes	637	636
Other	225	177
Total	$ 2,268	$ 2,167

Note 15 - Quarterly Financial Data (Unaudited) (Tables)

12 Months Ended

Dec. 31, 2023

Quarterly Financial Information [Table Text Block]

	Three months ended
2023	March 31		June 30		September 30		December 31
	(in thousands, except per share data)
Total net sales	$	47,075	$	50,115	$	47,411	$	48,883
Gross profit		30,883		32,086		30,815		33,265
Income from operations		7,874		9,452		9,180		10,206
Net income		6,040		8,098		7,502		8,465
Earnings per share
Basic	$	0.27	$	0.36	$	0.34	$	0.38
Diluted	$	0.27	$	0.36	$	0.33	$	0.38

	Three months ended
2022	March 31		June 30		September 30		December 31
	(in thousands, except per share data)
Total net sales	$	39,561	$	42,108	$	39,028	$	40,954
Gross profit		25,962		27,810		25,070		26,054
Income from operations		7,928		5,784		6,150		6,967
Net income		6,038		3,515		5,456		5,627
Earnings per share
Basic	$	0.28	$	0.16	$	0.25	$	0.26
Diluted	$	0.27	$	0.16	$	0.25	$	0.25

Note 5 - Goodwill and Other Intangibles (Details Textual)	Dec. 31, 2023
Minimum [Member]
Finite-Lived Intangible Asset, Useful Life	2 years
Maximum [Member]
Finite-Lived Intangible Asset, Useful Life	16 years
Weighted Average [Member]
Finite-Lived Intangible Asset, Useful Life	9 years 3 months 18 days

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Operating activities
Net income	$ 30,105	$ 20,636	$ 26,907
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	9,515	9,433	11,070
Stock-based compensation	5,319	4,173	3,479
Provision for inventory write-downs	2,237	2,572	3,779
Provision (benefit) for deferred income taxes	783	(182)	79
Loss on divestitures	485	1,954	0
Provision for credit losses	344	637	263
Fair value adjustments to contingent consideration obligations	(78)	(108)	(674)
Foreign currency transaction effect on income	(705)	(315)	163
Changes in operating assets and liabilities:
Accounts receivable	(3,135)	(3,533)	(818)
Inventory and other deferred costs	(9,794)	(7,418)	(5,485)
Prepaid expenses and other assets	(2,924)	(3,096)	(1,927)
Accounts payable and other liabilities	4,599	645	(1,734)
Net cash provided by operating activities	36,751	25,378	35,102
Investing activities
Purchases of short-term marketable securities	(16,551)	(8,000)	(59,194)
Purchases of property and equipment	(7,265)	(3,229)	(4,882)
Payments related to acquisitions	(899)	0	0
Proceeds from sale of building	0	858	0
Proceeds from sales of marketable securities	0	0	3,000
Net cash used in investing activities	24,715	10,371	61,076
Financing activities
Common stock cash dividend paid	(12,448)	(10,988)	(9,336)
Proceeds from issuance of common stock	6,170	3,466	63,241
Purchase of treasury stock for net settlement of equity awards	(853)	(642)	(802)
Payment of deferred acquisition consideration	0	(1,070)	(401)
Payments of long-term debt	0	0	(39,000)
Net cash provided by (used in) financing activities	(7,131)	(9,234)	13,702
Effect of exchange rate changes on cash and cash equivalents	230	(494)	(637)
Net increase (decrease) in cash and cash equivalents	5,135	5,279	(12,909)
Cash and cash equivalents at beginning of year	19,134	13,855	26,764
Cash and cash equivalents at end of year	24,269	19,134	13,855
Building [Member]
Adjustments to reconcile net income to net cash provided by operating activities:
Gain on sale of building	0	(115)	0
PPE Excluding Building [Member]
Adjustments to reconcile net income to net cash provided by operating activities:
Gain on sale of building	$ 0	$ 95	$ 0

Note 4 - Property and Equipment (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Impairment, Long-Lived Asset, Held-for-Use	$ 7.1	$ 0.5	$ 0.1

Note 3 - Inventory and Other Deferred Costs (Tables)

12 Months Ended

Dec. 31, 2023

Schedule of Inventory, Current [Table Text Block]

	December 31, 2023		December 31, 2022
	(in thousands)
Raw materials	$	18,333	$	14,929
Work-in-process		2,869		3,662
Finished products		31,131		26,688
Other deferred costs		5,747		4,992

Total inventory and other deferred costs	$	58,080	$	50,271

Insider Trading Arrangements

12 Months Ended

Dec. 31, 2023

Insider Trading Arr Line Items

Material Terms of Trading Arrangement [Text Block]

Item 9B.

Other Information

During the fiscal quarter ended December 31, 2023, none of our directors or officers adopted, modified or terminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement, as those terms are defined in Regulation S-K, Item 408.

Rule 10b5-1 Arrangement Adopted [Flag]

false

Non-Rule 10b5-1 Arrangement Adopted [Flag]

false

Rule 10b5-1 Arrangement Terminated [Flag]

false

Non-Rule 10b5-1 Arrangement Terminated [Flag]

false

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Net sales	$ 193,484	$ 161,651	$ 154,424
Cost of sales	66,435	56,755	53,042
Gross profit	127,049	104,896	101,382
Sales and marketing	41,054	32,921	27,655
General and administrative	31,832	28,745	25,501
Research and development	16,966	13,294	11,801
Restructuring	485	3,107	0
Total operating expenses	90,337	78,067	64,957
Income from operations	36,712	26,829	36,425
Other income (expense):	3,077	986	197
Interest expense	(0)	(0)	2,219
Other income (loss), net	(314)	(325)	(116)
Income before income taxes	39,475	27,490	34,287
Provision for income taxes	9,370	6,854	7,380
Net income	$ 30,105	$ 20,636	$ 26,907
Earnings per share of common stock: (in dollars per share)	$ 1.36	$ 0.94	$ 1.27
Diluted (in dollars per share)	$ 1.34	$ 0.93	$ 1.25
Weighted-average shares outstanding: (in shares)	22,217	21,975	21,157
Diluted (in shares)	22,423	22,171	21,475
Cash dividends declared per common share (in dollars per share)	$ 0.56	$ 0.5	$ 0.44

Note 13 - Fair Value Measurements - Rollforward of the Fair Value as Determined by Level 3 (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Beginning balance	$ 1,339	$ 1,492	$ 2,240
Additions	0	0	0
Payments	0	0	0
Change in fair value included in earnings	(115)	(153)	(748)
Ending balance	$ 1,224	$ 1,339	$ 1,492

Note 5 - Goodwill and Other Intangibles (Tables)

12 Months Ended

Dec. 31, 2023

Schedule of Goodwill [Table Text Block]

	As of December 31,
	2023		2022

Balance at beginning of year	$	65,945	$	65,945
Additions for acquisitions		-		-
Purchase accounting adjustments		-		-
Effects of currency exchange		-		-

Balance at end of year	$	65,945	$	65,945

Schedule of Finite-Lived Intangible Assets [Table Text Block]

	December 31, 2023						December 31, 2022
	Gross				Net		Gross				Net
	Carrying		Accumulated		Carrying		Carrying		Accumulated		Carrying
	Value		Amortization		Value		Value		Amortization		Value
	(in thousands)
Product technology and intellectual property	$	29,549	$	16,048	$	13,501	$	29,549	$	13,319	$	16,230
Trademarks, tradenames and licenses		3,767		1,909		1,858		3,647		1,533		2,114
Customer relationships		37,171		11,064		26,107		36,197		8,359		27,838
Other intangible assets		1,643		1,398		245		1,461		1,116		345

Total identifiable intangible assets	$	72,130	$	30,419	$	41,711	$	70,854	$	24,327	$	46,527

Finite-Lived Intangible Assets Amortization Expense [Table Text Block]

	Year ended December 31,
	2023		2022		2021
			(in thousands)

Amortization expense	$	6,092	$	6,183	$	6,195

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

	Year ended December 31,
	2024		2025		2026		2027		2028
	(in thousands)

Amortization expense	$	5,904	$	5,554	$	5,119	$	4,842	$	4,456

Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482548/350-20-55-24

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1A

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-2

Note 1 - Significant Accounting Policies and Related Matters

12 Months Ended

Dec. 31, 2023

Significant Accounting Policies [Text Block]

1. Significant Accounting Policies and Related Matters

Description of Business

Consolidation and Basis of Presentation

Foreign Currency Translation

Estimates

Revenue Recognition

Step 1: Identify the contract with a customer

Step 2: Identify the performance obligations in the contract

Step 3: Determine the transaction price

Step 4: Allocate the transaction price to the performance obligations

Step 5: Recognize revenue when or as the entity satisfies a performance obligation

	Year ended December 31,
	2023		2022		2021
Americas	$	130,308	$	109,439	$	102,265
Europe, Middle East and Africa		51,099		41,854		42,132
Asia Pacific		12,077		10,358		10,027
Total	$	193,484	$	161,651	$	154,424

Research and Development Expense

Shipping and Handling Costs

Shipping and handling fees paid by customers are recorded within net sales, with the related expense recorded in cost of sales.

Advertising Costs

Advertising costs are expensed as incurred and are included as a component of sales and marketing expense in the accompanying consolidated statements of operations. Advertising costs are as follows:

	Year ended December 31,
	2023		2022		2021
			(in thousands)

Advertising expense	$	240	$	195	$	236

Cash and Cash Equivalents

Short-term Marketable Securities

Concentrations of Credit Risk

	Balance at		Additions		Deductions		Balance at
	Beginning		(recoveries) charged		from		End of
	of Period		to Income		Reserves		Period
	(in thousands)
Allowance for credit losses and sales returns:
Year ended December 31, 2023	$	835	$	344	$	238	$	941
Year ended December 31, 2022		679		637		481		835
Year ended December 31, 2021		623		263		207		679

Fair Value of Financial Instruments

Inventory and Other Deferred Costs

Cloud Computing Arrangements

Property and Equipment

Property and equipment are recorded at cost. Depreciation is provided over the estimated useful lives of the related assets using straight-line method as follows:

Description	Useful Life (in years)
Computer hardware	3	–	5
Machinery and equipment	3	–	10
Building and leasehold improvements	The shorter of its useful life or lease term

Valuation of Business Combinations

Contingent Consideration

Contingent consideration for acquisitions is recognized at the date of acquisition, based on the fair value at that date, and then re-measured periodically through adjustments to net income.

Impairment of Long-lived Assets

Goodwill

Other Intangible Assets

Stock-based Compensation

Commitments and Contingencies

Income Taxes

Our policy is to classify interest and penalties related to unrecognized tax benefits as income tax expense.

Comprehensive Income

Restructuring

Earnings per Share

The computation of basic and diluted net income per share is as follows:

		Year ended December 31,
	2023		2022		2021
		(in thousands, except per share data)
Basic:
Net income available for common stockholders	$	30,105	$	20,636	$	26,907

Weighted average shares outstanding		22,217		21,975		21,157

Basic earnings per share	$	1.36	$	0.94	$	1.27

Diluted:
Net income available for common stockholders	$	30,105	$	20,636	$	26,907

Weighted-average shares outstanding		22,217		21,975		21,157
Common stock equivalents, if dilutive		206		196		318

Shares used in computing diluted earnings per common share		22,423		22,171		21,475

Diluted earnings per share	$	1.34	$	0.93	$	1.25

Shares excluded in computing diluted earnings per share as those shares would be anti-dilutive		295		293		10

Recent Accounting Pronouncements

Not Yet Effective

Note 9 - Income Taxes - Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Unrecognized tax benefits at the beginning of year	$ 612	$ 768	$ 820
Additions/adjustments for tax positions of current year	0	0	0
Additions/adjustments for tax positions of prior years	(25)	(57)	(52)
Reductions for settlements with taxing authorities	0	0	0
Reductions for lapses of the applicable statutes of limitations	0	(99)	0
Unrecognized tax benefits at the end of the year	$ 587	$ 612	$ 768

Note 7 - Accrued Expenses and Other Long-term Liabilities

12 Months Ended

Dec. 31, 2023

Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Noncurrent [Text Block]

7. Accrued Expenses and Other Long-term Liabilities

Accrued expenses consist of the following:

	December 31, 2023		December 31, 2022
	(in thousands)
Compensation and related taxes	$	13,353	$	10,770
Accrued purchases		5,152		3,748
Accrued expenses		4,251		4,640
Income and other taxes		390		449
Professional fees		104		108
Other		400		252

Total	$	23,650	$	19,967

Other long-term liabilities consist of the following:

	December 31, 2023		December 31, 2022
	(in thousands)
Acquisition-related liabilities	$	1,406	$	1,354
Income taxes		637		636
Other		225		177

Total	$	2,268	$	2,167

Note 7 - Accrued Expenses and Other Long-term Liabilities (Tables)

12 Months Ended

Dec. 31, 2023

Schedule of Accrued Liabilities [Table Text Block]

	December 31, 2023		December 31, 2022
	(in thousands)
Compensation and related taxes	$	13,353	$	10,770
Accrued purchases		5,152		3,748
Accrued expenses		4,251		4,640
Income and other taxes		390		449
Professional fees		104		108
Other		400		252

Total	$	23,650	$	19,967

Other Noncurrent Liabilities [Table Text Block]

	December 31, 2023		December 31, 2022
	(in thousands)
Acquisition-related liabilities	$	1,406	$	1,354
Income taxes		637		636
Other		225		177

Total	$	2,268	$	2,167

Note 11 - Profit-sharing Plan (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Defined Contribution, Plan Employers Matching Contribution, Annual Vesting Period	6 years
Deferred Profit Sharing [Member]
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 0.8	$ 0.6	$ 0.5

Note 14 - Accumulated Other Comprehensive Income (Loss) (Tables)

12 Months Ended

Dec. 31, 2023

Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]

	Year ended December 31,
	2023			2022			2021
	(in thousands)
Beginning balance	$	(6,031	)	$	(3,435	)	$	(1,525	)

Other comprehensive income (loss) before reclassifications		1,406			(2,596	)		(1,910	)
Amounts reclassified from accumulated other comprehensive loss		-			-			-

Ending Balance	$	(4,625	)	$	(6,031	)	$	(3,435	)

Note 12 - Segment and Enterprise-wide Disclosures - Long-term Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Long-term Assets	$ 39,781	$ 33,535
UNITED STATES
Long-term Assets	34,729	29,042
GERMANY
Long-term Assets	2,350	2,462
Other Countries [Member]
Long-term Assets	$ 2,702	$ 2,031

Note 10 - Stockholders' Equity

12 Months Ended

Dec. 31, 2023

Equity [Text Block]

10. Stockholders’ Equity

Authorized Shares

Our certificate of incorporation, as amended and restated from time to time, authorizes the issuance of up to 37,000,000 shares of common stock and up to 3,000,000 shares of undesignated preferred stock.

Under the terms of our certificate of incorporation, our board of directors is authorized to issue shares of the preferred stock in one or more series without stockholder approval. Our board of directors has the discretion to determine the rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock. Currently, we have no shares of preferred stock outstanding.

Equity Offering

On July 16, 2021, we closed an offering of 1,000,000 shares of our common stock, $0.01 par value per share, at a price to the public of $54.50 per share, less underwriting discounts. The net proceeds, after deducting the underwriting discounts and other offering expenses, were approximately $51.0 million. We used a portion of the proceeds from the offering to repay our outstanding debt. At the time of the offering we intended to use the remaining proceeds for general corporate purposes, including working capital needs and capital expenditures, dividend payments, deferred payments related to prior acquisitions, and the funding of future acquisitions.

On August 4, 2021, the underwriters purchased an additional 150,000 shares pursuant to an option granted to them in connection with the offering described above. The net proceeds to the Company, after deducting underwriting discounts and other offering expenses, were approximately $7.6 million. At the time of the offering, we intended to use the proceeds for general corporate purposes.

Stock Award Plans

In May 2006 we approved a 2006 Stock Option and Incentive Plan (as subsequently amended, the 2006 Plan), which became effective upon our initial public offering. The 2006 Plan allows for the granting of an aggregate 5,500,000 shares of incentive stock options, non-qualified stock options, stock appreciation rights, RSUs, PSUs, unrestricted stock awards, and deferred stock awards to our officers, employees, directors, and consultants. Incentive stock options are required to be issued at not less than fair market value at the date of the grant and generally vest over four or five years. The term of the options is determined by our Board of Directors but in no event will exceed ten years from date of grant. In connection with the adoption of the 2006 Plan, no further option grants were permitted under any previous stock option plans and any expirations, cancellations, or terminations under the previous plans are available for issuance under the 2006 Plan. We may satisfy awards upon exercise of stock options, RSUs or PSUs with either newly issued shares or treasury shares. The total number of shares currently authorized for the 2006 Plan is 7,118,003 shares, of which 273,588 remain available for grant as of December 31, 2023.

We have computed the fair value of employee stock options granted each year using the following weighted average assumptions:

	2023			2022			2021
Dividend yield		1.02	%		1.06	%		0.91	%
Volatility		43.0	%		44.6	%		46.0	%
Risk-free interest rate		4.3	%		3.9	%		1.1	%
Weighted average expected option term (in years)		4.5			4.5			4.6
Weighted average fair value per share of options granted	$	20.75		$	18.10		$	17.64

A summary of option activity as of December 31, 2023 and for the three years then ended is presented below:

				Weighted		Weighted Average		Aggregate
	Number			Average		Remaining		Intrinsic
	of Shares			Exercise Price		Contractual Term		Value
						(in years)		(in thousands)

Balance outstanding at December 31, 2020		931,840		$	28.22		4.49	$	11,442

Granted		151,161		$	48.60
Exercised		(217,121	)	$	20.95			$	6,975
Canceled / Expired		(19,126	)	$	23.18
Balance outstanding at December 31, 2021		846,754		$	33.83		4.50	$	13,888

Granted		159,275		$	47.21
Exercised		(133,963	)	$	25.80			$	3,021
Canceled / Expired		(12,091	)	$	35.53
Balance outstanding at December 31, 2022		859,975		$	37.53		4.35	$	7,878

Granted		148,115		$	54.71
Exercised		(207,643	)	$	29.72			$	5,914
Canceled / Expired		(19,323	)	$	41.55
Balance outstanding at December 31, 2023		781,124		$	42.78		4.42	$	10,924

Exercisable at:
December 31, 2021		301,692		$	27.40		3.30	$	6,886
December 31, 2022		369,593		$	32.16		3.17	$	5,223
December 31, 2023		356,519		$	36.83		3.21	$	7,107

Expected to vest at:
December 31, 2021		545,062		$	37.38		5.16
December 31, 2022		490,382		$	41.59		5.23
December 31, 2023		424,605		$	47.78		5.43

Cash received from stock options exercised during the years ended December 31, 2023, 2022 and 2021 was $6.2 million, $3.5 million and $4.5 million, respectively.

Restricted Stock Units and Performance-based Restricted Stock Units

The fair value of restricted stock unit awards with time-based vesting is based on the intrinsic value of the awards at the date of grant.

We also issue restricted stock unit awards with vesting based on performance conditions. Performance-based restricted stock units awarded vest based on our achievement of operating income relative to our target operating income. For restricted stock unit awards that include vesting based on performance conditions, the fair values are based on the intrinsic values of the awards at the date of grant.

A summary of our restricted stock unit activity as of December 31, 2023 and for the three years then ended is presented below:

				Weighted
				Average
	Number			Grant Date
	of Shares			Fair Value

Balance outstanding at December 31, 2020		147,015		$	30.24

Granted		48,298		$	48.65
Vested		(51,414	)	$	26.32
Canceled		(10,068	)	$	30.70

Balance outstanding at December 31, 2021		133,831		$	38.26

Granted		51,031		$	47.11
Vested		(45,489	)	$	35.75
Canceled		(6,229	)	$	40.79

Balance outstanding at December 31, 2022		133,144		$	42.38

Granted		48,225		$	54.68
Vested		(49,400	)	$	39.31
Canceled		(5,975	)	$	42.89

Balance outstanding at December 31, 2023		125,994		$	48.20

The number of RSUs vested includes the shares that we withheld on behalf of employees to satisfy minimum statutory tax withholding requirements. The fair values of the RSUs that vested during 2023, 2022 and 2021 were $2.7 million, $2.1 million, and $2.5 million, respectively.

We repurchase shares of our common stock in order to cover any minimum tax withholding liability associated with RSU vestings. A summary of our repurchases is as follows:

	2023		2022		2021

Shares of common stock repurchased for net settlement of equity awards		15,917		13,690		16,333
Average per share repurchase price	$	53.59	$	46.90	$	49.10
Aggregate purchase price (in thousands)	$	853	$	642	$	802

A summary of our performance-based restricted stock unit activity as of December 31, 2023 and for the three years then ended is presented below:

				Weighted
				Average
	Number			Grant Date
	of Shares			Fair Value

Balance outstanding at December 31, 2020		-		$	-

Granted		31,181		$	48.60
Vested		-		$	-
Canceled		-		$	-

Balance outstanding at December 31, 2021		31,181		$	48.60

Granted		28,830		$	47.13
Vested		-		$	-
Canceled		(31,538	)	$	48.53

Balance outstanding at December 31, 2022		28,473		$	47.19

Granted		26,883		$	54.65
Vested		-		$	-
Canceled		(1,192	)	$	47.19

Balance outstanding at December 31, 2023		54,164		$	50.85

Stock-based Compensation

The components of stock-based compensation expense included in the consolidated statements of operations are as follows:

	2023		2022		2021
			(in thousands)
Stock option awards	$	2,705	$	2,487	$	2,199
Restricted stock units		1,951		1,654		1,247
Performance-based restricted stock units		663		32		33

Total stock-based compensation	$	5,319	$	4,173	$	3,479

Stock-based compensation is included in our statements of operations as follows:

	2023		2022		2021
			(in thousands)
Cost of sales	$	686	$	494	$	407
Sales and marketing		966		771		527
General and administrative		3,143		2,500		2,185
Research and development		524		408		360

Total stock-based compensation	$	5,319	$	4,173	$	3,479

We expect to record the unamortized portion of share-based compensation expense of $15.1 million for existing stock options, RSUs and PSUs outstanding as of December 31, 2023, over a weighted-average period of 2.0 years.

Stock Repurchase Plans

On February 21, 2024, our Board of Directors authorized the repurchase of up to $50.0 million of the Company’s common stock through transactions on the open market, in privately negotiated purchases or otherwise until February 21, 2025. The repurchase program may be suspended or discontinued at any time. To date we have not made any repurchases under this program.

Dividends

In February 2011, our Board of Directors approved a policy for the payment of quarterly cash dividends on our common stock. Future declarations of quarterly dividends and the establishment of future record and payment dates are subject to approval by our Board of Directors on a quarterly basis. The dividend activity for the periods presented is as follows:

Record Date	Payment Date	Per Share Amount		Dividend Payment
				(in thousands)
Fiscal Year 2023
March 9, 2023	March 23, 2023	$	0.140	$	3,099
May 17, 2023	June 1, 2023	$	0.140	$	3,116
August 17, 2023	August 31, 2023	$	0.140	$	3,117
November 16, 2023	November 30, 2023	$	0.140	$	3,117

Fiscal Year 2022
March 8, 2022	March 24, 2022	$	0.125	$	2,743
May 17, 2022	June 2, 2022	$	0.125	$	2,745
August 25, 2022	September 8, 2022	$	0.125	$	2,750
November 17, 2022	December 1, 2022	$	0.125	$	2,750

On February 21, 2024, our Board of Directors approved a quarterly cash dividend on our common stock of $0.160 per share payable on March 28, 2024, to stockholders of record at the close of business on March 14, 2024, which will total approximately $3.6 million.

The entire disclosure for equity.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481004/946-505-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480237/815-40-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Note 4 - Property and Equipment (Tables)

12 Months Ended

Dec. 31, 2023

Property, Plant and Equipment [Table Text Block]

	As of December 31,
	2023			2022
	(in thousands)
Computer hardware	$	5,319		$	5,689
Machinery and equipment		16,942			22,104
Building and leasehold improvements		20,981			15,232

Gross property and equipment		43,242			43,025
Less accumulated depreciation		(21,488	)		(25,124	)

Property and equipment, net	$	21,754		$	17,901

Depreciation Expense [Table Text Block]

	Year ended December 31,
	2023		2022		2021
			(in thousands)

Depreciation expense	$	3,423	$	3,250	$	3,280

Note 9 - Income Taxes - Schedule of Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Cash paid for income taxes, net	$ 7,549	$ 8,343	$ 10,147

Note 15 - Quarterly Financial Data (Unaudited)

12 Months Ended

Dec. 31, 2023

Quarterly Financial Information [Text Block]

15. Quarterly Financial Data (unaudited)

	Three months ended
2023	March 31		June 30		September 30		December 31
	(in thousands, except per share data)
Total net sales	$	47,075	$	50,115	$	47,411	$	48,883
Gross profit		30,883		32,086		30,815		33,265
Income from operations		7,874		9,452		9,180		10,206
Net income		6,040		8,098		7,502		8,465
Earnings per share
Basic	$	0.27	$	0.36	$	0.34	$	0.38
Diluted	$	0.27	$	0.36	$	0.33	$	0.38

	Three months ended
2022	March 31		June 30		September 30		December 31
	(in thousands, except per share data)
Total net sales	$	39,561	$	42,108	$	39,028	$	40,954
Gross profit		25,962		27,810		25,070		26,054
Income from operations		7,928		5,784		6,150		6,967
Net income		6,038		3,515		5,456		5,627
Earnings per share
Basic	$	0.28	$	0.16	$	0.25	$	0.26
Diluted	$	0.27	$	0.16	$	0.25	$	0.25

Note 10 - Stockholders' Equity - Dividend Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Cash dividends declared per common share (in dollars per share)	$ 0.56	$ 0.5	$ 0.44
Quarterly Dividends 1 [Member]
Payment Date	Mar. 23, 2023	Mar. 24, 2022
Cash dividends declared per common share (in dollars per share)	$ 0.14	$ 0.125
Dividend Payment	$ 3,099	$ 2,743
Quarterly Dividends 2 [Member]
Payment Date	Jun. 01, 2023	Jun. 02, 2022
Cash dividends declared per common share (in dollars per share)	$ 0.14	$ 0.125
Dividend Payment	$ 3,116	$ 2,745
Quarterly Dividends 3 [Member]
Payment Date	Aug. 31, 2023	Sep. 08, 2022
Cash dividends declared per common share (in dollars per share)	$ 0.14	$ 0.125
Dividend Payment	$ 3,117	$ 2,750
Quarterly Dividends 4 [Member]
Payment Date	Nov. 30, 2023	Dec. 01, 2022
Cash dividends declared per common share (in dollars per share)	$ 0.14	$ 0.125
Dividend Payment	$ 3,117	$ 2,750

Note 8 - Commitments and Contingencies

12 Months Ended

Dec. 31, 2023

Commitments and Contingencies Disclosure [Text Block]

8. Commitments and Contingencies

Leases

The Company determines if an arrangement is a lease at inception of the contract. The Company has operating leases for buildings, primarily for office space, manufacturing and distribution, as well as automobiles and printing equipment. As of December 31, 2023, the Company had the following building and facility leases capitalized on the balance sheet:

	Location (leases)	Purpose	Approx. Sq. Ft.	Expiration

Americas
	Burlington, MA (4)	Corporate headquarters and manufacturing	96,476	December 2034
	North Brunswick, NJ (1)	Artegraft biologic business	16,732	October 2029
	Burlington, MA (1)	US distribution	12,878	December 2030
	Fox River Grove, IL (3)	RestoreFlow allografts business	11,765	November 2025
	Vaughn, Canada	Canada sales office and distribution	3,192	February 2026
	Chandler, Arizona	US sales office	2,058	August 2025

Europe, Middle East and Africa
	Sulzbach, Germany	European headquarters and distribution	21,410	June 2031
	Milan,Italy	Italy sales office and distribution	5,705	July 2027
	Hereford, England	United Kingdom sales office and distribution	3,575	October 2029
	Madrid, Spain	Spain sales office	2,260	June 2029

Asia Pacific
	Singapore	Asia Pacific headquarters and distribution	1,270	June 2024
	Tokyo, Japan	Japan sales office and distribution	4,236	July 2025
	Bangkok, Thailand	Thailand sales office and distribution	2,810	August 2026
	Seoul, Korea	Korea sales office and distribution	2,300	April 2027
	Shanghai, China	China sales office and distribution	1,152	August 2024
	Ballarat, Australia	Supply facility	Up to 350 acres	December 2030

Operating lease right-of-use (ROU) assets and operating lease liabilities are recognized based on the present value of the future lease minimum payments over the lease term at commencement date. Many of the lease agreements contain renewal or termination clauses that are factored into the determination of the lease term if it is reasonably certain that these options would be exercised. The Company recognizes lease expense for these leases on a straight-line basis over the lease term.

None of our noncancelable lease payments include non-lease components such as maintenance contracts; we generally reimburse the landlord for direct operating costs associated with the leased space. We have no subleases, and there are no residual value guarantees associated with, or restrictive covenants imposed by, any of our leases. There were no assets held under capital leases as of December 31, 2023. We elected the package of practical expedients that allow us to omit leases with initial terms of 12 months or less from our balance sheet, which are expensed on a straight-line basis over the life of the lease.

The interest rate implicit in lease agreements is typically not readily determinable, and as such the Company used the incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The incremental borrowing rate is defined as the interest the Company would pay to borrow on a collateralized basis.

Additional information with respect to our leases is as follows:

	Year ended			Year ended
	December 31,			December 31,
	2023			2022
	(in thousands)			(in thousands)

Lease cost
Operating lease cost	$	2,420		$	2,203
Short-term lease cost		378			632
Total lease cost	$	2,798		$	2,835

Other information
Cash paid for amounts included in the measurement of operating lease liabilities	$	3,139		$	2,878

Right-of-use assets obtained in exchange for new operating lease liabilities	$	4,813		$	2,766


Weighted average remaining lease term - operating leases (in years)		7.3			7.1

Weighted average discount rate - operating leases		6.57	%		4.93	%

As of December 31, 2023, the minimum noncancelable operating lease rental commitments with initial or remaining terms of more than one year are as follows:

Year ending December 31,
2024	$	3,622
2025		3,364
2026		2,699
2027		2,503
2028		2,469
Thereafter		10,906
Adjustment to net present value as of December 31, 2023		(6,468	)

Minimum noncancelable lease liability	$	19,095

Purchase Commitments

As part of our normal course of business, we have commitments to purchase approximately $5.1 million of inventory through 2024. These purchases are to be used in the normal course of business and do not represent excess commitments or loss contracts.

Note 1 - Significant Accounting Policies and Related Matters - Summary of Property and Equipment (Details)	Dec. 31, 2023
Computers and Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment, Useful Life	3 years
Computers and Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment, Useful Life	5 years
Machinery and Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment, Useful Life	3 years
Machinery and Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment, Useful Life	10 years

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Treasury Stock, Common [Member]	Total
Balance (in shares) at Dec. 31, 2020	22,061,554				1,538,572
Balance at Dec. 31, 2020	$ 221	$ 114,924	$ 70,554	$ (1,525)	$ (11,602)	$ 172,572
Net income			26,907			26,907
Other comprehensive income (loss)				(1,910)		(1,910)
Issuance of common stock, net of issuance costs (in shares)	1,150,000
Issuance of common stock, net of issuance costs	$ 12	58,683				$ 58,695
Issuance of common stock for stock options exercised (in shares)	217,121					133,963
Issuance of common stock for stock options exercised	$ 2	4,544				$ 4,546
Vested restricted stock units (in shares)	49,109
Vested restricted stock units	$ 0	0				0
Stock-based compensation expense		3,479				3,479
Repurchase of common stock for net settlement of equity awards (in shares)					16,333
Repurchase of common stock for net settlement of equity awards					$ (802)	(802)
Common stock cash dividend paid			(9,336)			(9,336)
Balance (in shares) at Dec. 31, 2021	23,477,784				1,554,905
Balance at Dec. 31, 2021	$ 235	181,630	88,125	(3,435)	$ (12,404)	254,151
Net income			20,636			20,636
Other comprehensive income (loss)				(2,596)		$ (2,596)
Issuance of common stock for stock options exercised (in shares)	133,963					207,643
Issuance of common stock for stock options exercised	$ 1	3,465				$ 3,466
Vested restricted stock units (in shares)	43,969
Vested restricted stock units	$ 1	0				1
Stock-based compensation expense		4,173				4,173
Repurchase of common stock for net settlement of equity awards (in shares)					13,690
Repurchase of common stock for net settlement of equity awards					$ (642)	(642)
Common stock cash dividend paid			(10,988)			(10,988)
Balance (in shares) at Dec. 31, 2022	23,655,716				1,568,595
Balance at Dec. 31, 2022	$ 237	189,268	97,773	(6,031)	$ (13,046)	268,201
Net income			30,105			30,105
Other comprehensive income (loss)				1,406		1,406
Issuance of common stock for stock options exercised (in shares)	207,643
Issuance of common stock for stock options exercised	$ 2	6,168				6,170
Vested restricted stock units (in shares)	48,401
Vested restricted stock units	$ 0	0				0
Stock-based compensation expense		5,319				5,319
Repurchase of common stock for net settlement of equity awards (in shares)					15,917
Repurchase of common stock for net settlement of equity awards					$ (853)	(853)
Common stock cash dividend paid			(12,448)			(12,448)
Balance (in shares) at Dec. 31, 2023	23,911,760				1,584,512
Balance at Dec. 31, 2023	$ 239	$ 200,755	$ 115,430	$ (4,625)	$ (13,899)	$ 297,900

Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Net income	$ 30,105	$ 20,636	$ 26,907
Other comprehensive income (loss):
Foreign currency translation adjustment, net	734	(1,071)	(1,604)
Unrealized gain (loss) on short-term marketable securities	672	(1,525)	(306)
Total other comprehensive income (loss)	1,406	(2,596)	(1,910)
Comprehensive income	$ 31,511	$ 18,040	$ 24,997

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-8

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-9

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-10

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483581/946-220-45-7

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-7

Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B

Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

Note 5 - Goodwill and Other Intangibles - Estimated Amortization Expense for Each of Five Succeeding Fiscal Years (Details) $ in Thousands	Dec. 31, 2023 USD ($)
2023	$ 5,904
2024	5,554
2025	5,119
2026	4,842
2027	$ 4,456

Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Accounts Receivable, Allowance for Credit Loss, Current	$ 941	$ 835
Preferred Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.01	$ 0.01
Preferred Stock, Shares Authorized (in shares)	3,000,000	3,000,000
Preferred Stock, Shares Outstanding, Ending Balance (in shares)	0	0
Common Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.01	$ 0.01
Common Stock, Shares Authorized (in shares)	37,000,000	37,000,000
Common Stock, Shares, Issued (in shares)	23,911,760	23,655,716
Treasury Stock, Common, Shares (in shares)	1,584,512	1,568,595

Note 5 - Goodwill and Other Intangibles

12 Months Ended

Dec. 31, 2023

Goodwill and Intangible Assets Disclosure [Text Block]

5. Goodwill and Other Intangibles

Goodwill consists of the following:

	As of December 31,
	2023		2022

Balance at beginning of year	$	65,945	$	65,945
Additions for acquisitions		-		-
Purchase accounting adjustments		-		-
Effects of currency exchange		-		-

Balance at end of year	$	65,945	$	65,945

Other intangibles consist of the following:

	December 31, 2023						December 31, 2022
	Gross				Net		Gross				Net
	Carrying		Accumulated		Carrying		Carrying		Accumulated		Carrying
	Value		Amortization		Value		Value		Amortization		Value
	(in thousands)
Product technology and intellectual property	$	29,549	$	16,048	$	13,501	$	29,549	$	13,319	$	16,230
Trademarks, tradenames and licenses		3,767		1,909		1,858		3,647		1,533		2,114
Customer relationships		37,171		11,064		26,107		36,197		8,359		27,838
Other intangible assets		1,643		1,398		245		1,461		1,116		345

Total identifiable intangible assets	$	72,130	$	30,419	$	41,711	$	70,854	$	24,327	$	46,527

These assets are being amortized over useful lives ranging from 2 to 16 years. The weighted-average amortization period for these intangibles as of December 31, 2023, is 9.3 years. Amortization expense is included in general and administrative expense and is as follows:

	Year ended December 31,
	2023		2022		2021
			(in thousands)

Amortization expense	$	6,092	$	6,183	$	6,195

Estimated amortization expense for each of the next five fiscal years, based upon the intangible assets at December 31, 2023, is as follows:

	Year ended December 31,
	2024		2025		2026		2027		2028
	(in thousands)

Amortization expense	$	5,904	$	5,554	$	5,119	$	4,842	$	4,456

Note 13 - Fair Value Measurements

12 Months Ended

Dec. 31, 2023

Fair Value Disclosures [Text Block]

13. Fair Value Measurements

The fair value accounting guidance requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories:

•

Level 1 — Quoted prices in active markets for identical assets or liabilities.

•

Level 2 — Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.

•

Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs.

Level 1 assets being measured at fair value on a recurring basis as of December 31, 2023 included our short-term investment and short-duration bond mutual fund accounts.

We had no Level 2 assets being measured at fair value on a recurring basis as of December 31, 2023.

Several of our acquisition-related assets and liabilities have been measured using Level 3 techniques. During 2020 we recorded a contingent liability associated with our acquisition of the bovine carotid graft business from Artegraft. The agreement required us to make potential additional payments to Artegraft of up to $17.5 million, depending on the achievement of certain unit sales milestones during the first three calendar years following the acquisition through December 31, 2023. We recorded this liability at a fair value of $0.4 million in 2020 to reflect management’s estimate of the likelihood of achieving these targets at the time of the Closing, as well as the time value of money until payment. This amount was being remeasured each quarter during the earn-out period, with any adjustments recorded in income from operations. As of December 31, 2023, there were no unit sales milestones achieved during the earn-out period and therefore we reduced the remaining liability to zero. As a result, during the quarter ended December 31, 2023, we recorded a reduction to the remaining liability of $0.1 million with the offset recorded in income from operations.

During 2019, we recorded contingent liabilities associated with our acquisition of the Anteris biologic patch business. The agreement includes the potential for us to pay up to $7.8 million of additional consideration beyond payments made to date, with $0.3 million contingent upon the delivery of audited financial statements of the acquired business to us; $2.0 million (CE Mark Contingency) contingent on LeMaitre’s success in obtaining CE marks under MDR regulations on the acquired products, $0.5 million contingent upon Anteris’ success in extending the shelf life of the acquired products as specified in the agreement; and another $5.0 million contingent on the achievement of specified levels of revenues in the first 12 and 24 months following the acquisition date. This additional contingent consideration was initially valued in total at $2.3 million and is being remeasured each quarter until the payment requirement ends, with any adjustments reported in income from operations. The contingent payment related to the delivery of audited financial statements of the business was paid in November 2019 upon satisfaction of the deliverable. The contingent payments related to Anteris’ extending the shelf life of the acquired products and achieving the revenue targets during the first 12 and 24 month periods following the acquisition were not met, and the portion of the liabilities related to these items was adjusted through income from operations. The agreement was amended in August 2021 such that the CE Mark Contingency amount may be reduced for certain costs incurred by LeMaitre in achieving the CE marks. During the quarter ended September 30, 2021 we recorded a reduction to the liability of $0.5 million, with the offset recorded in income from operations, to reflect our estimate of costs to be deducted from the contingent payment in connection with this amendment. Additionally, during the quarter ended December 31, 2022 we recorded a reduction to the liability of approximately $0.1 million, with the offset recorded in income from operations.

In September 2023, the agreement was further amended in order to (i) place a cap on the total amount of costs incurred by LeMaitre in achieving the CE marks under MDR regulations that could be used as a deduction toward the $2.0 million holdback, and (ii) require a prorata payment to Anteris of the CE Mark Contingency, less costs described above, by January 2025 if the CE marks are not obtained by that date. During the quarter ended September 30, 2023 we recorded a reduction to the liability of $0.1 million, with the offset recorded in income from operations.

The following table provides a roll-forward of the fair value of these liabilities, as determined by Level 3 unobservable inputs including management’s forecast of future revenues for the acquired businesses, as well as, management’s estimates of the likelihood of achieving the other specified criteria:

	Year ended December 31,
	2023			2022			2021
	(in thousands)
Beginning balance	$	1,339		$	1,492		$	2,240
Additions		-			-			-
Payments		-			-			-
Change in fair value included in earnings		(115	)		(153	)		(748	)

Ending balance	$	1,224		$	1,339		$	1,492

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

Note 9 - Income Taxes - Reconciliation of the Federal Statutory Rate to Effective Tax Rate (Details)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Federal statutory rate	21.00%	21.00%	21.00%
State tax, net of federal benefit	2.80%	2.70%	2.70%
Effect of foreign taxes	1.70%	4.00%	3.70%
Federal tax on foreign income	0.30%	0.00%	0.20%
Valuation allowance	0.20%	0.20%	0.10%
Valuation allowance	(0.20%)	(0.20%)	(0.10%)
Foreign deferred tax liability offset	(0.10%)	(0.20%)	(0.10%)
Research & development tax credits	(0.60%)	0.00%	(0.40%)
Stock options	(1.80%)	0.00%	(3.10%)
Uncertain tax positions	0.10%	0.30%	0.20%
Uncertain tax positions	(0.10%)	(0.30%)	(0.20%)
Other permanent differences	0.40%	1.80%	2.40%
Other permanent differences	(0.40%)	(1.80%)	(2.40%)
Other	(0.30%)	(0.30%)	(0.20%)
Effective tax rate	23.70%	24.90%	21.50%

Document And Entity Information - USD ($) $ in Billions	12 Months Ended
Document And Entity Information - USD ($) $ in Billions	Dec. 31, 2023	Feb. 27, 2024	Jun. 30, 2023
Document Information [Line Items]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2023
Document Transition Report	false
Entity File Number	001-33092
Entity Registrant Name	LEMAITRE VASCULAR, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	04-2825458
Entity Address, Address Line One	63 Second Avenue
Entity Address, City or Town	Burlington
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01803
City Area Code	781
Local Phone Number	221-2266
Title of 12(b) Security	Common stock, $0.01 par value per share
Trading Symbol	LMAT
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Document Financial Statement Error Correction [Flag]	false
Entity Shell Company	false
Entity Public Float			$ 1.3
Entity Common Stock, Shares Outstanding (in shares)		22,337,216
Auditor Firm ID	248
Auditor Name	GRANT THORNTON LLP
Auditor Location	Boston, Massachusetts
Entity Central Index Key	0001158895
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	FY
Amendment Flag	false

Note 9 - Income Taxes - Income (Loss) Before Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
United States	$ 37,356	$ 26,274	$ 34,153
Foreign	2,119	1,216	134
Income before income taxes	$ 39,475	$ 27,490	$ 34,287

Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(11))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-SubTopic 20
-Topic 940
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481913/940-20-25-1

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

Note 10 - Stockholders' Equity (Details Textual) - USD ($)				12 Months Ended
	Feb. 21, 2024	Aug. 04, 2021	Jul. 16, 2021	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Common Stock, Shares Authorized				37,000,000	37,000,000
Preferred Stock, Shares Authorized				3,000,000	3,000,000
Preferred Stock, Shares Outstanding, Ending Balance (in shares)				0	0
Stock Issued During Period, Shares, New Issues			1,000,000
Common Stock, Par or Stated Value Per Share			$ 0.01	$ 0.01	$ 0.01
Shares Issued, Price Per Share			$ 54.5
Stock Issued During Period, Value, New Issues			$ 51,000,000			$ 58,695,000
Proceeds from Issuance of Common Stock				$ 6,170,000	$ 3,466,000	63,241,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized				5,500,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period				10 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized				7,118,003
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant				273,588
Proceeds from Stock Options Exercised				$ 6,200,000	$ 3,500,000	$ 4,500,000
Common Stock, Dividends, Per Share, Declared				$ 0.56	$ 0.5	$ 0.44
Subsequent Event [Member]
Common Stock, Dividends, Per Share, Declared	$ 0.16
Dividends Payable, Date to be Paid	Mar. 28, 2024
Dividends Payable, Date of Record	Mar. 14, 2024
Dividends Payable	$ 3,600,000
Common Stock [Member]
Stock Issued During Period, Shares, New Issues						1,150,000
Stock Issued During Period, Value, New Issues						$ 12,000
Stock Repurchase Program [Member] \| Common Stock [Member]
Treasury Stock, Shares, Acquired (in shares)						0
Stock Repurchase Program [Member] \| Common Stock [Member] \| Subsequent Event [Member]
Stock Repurchase Program, Authorized Amount	$ 50,000,000
Share-Based Payment Arrangement, Option [Member] \| Share-Based Payment Arrangement, Tranche One [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period				4 years
Share-Based Payment Arrangement, Option [Member] \| Share-Based Payment Arrangement, Tranche Two [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period				5 years
Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value				$ 2,700,000	$ 2,100,000	$ 2,500,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount				$ 15,100,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition				2 years
Underwriters [Member]
Stock Issued During Period, Value, New Issues		$ 150,000
Proceeds from Issuance of Common Stock		$ 7,600,000

Note 2 - Divestures (Details Textual) - USD ($) $ in Millions		12 Months Ended
	Oct. 10, 2022	Dec. 31, 2022
Restructuring Charges		$ 3.1
St. Etienne, France Factory [Member]
Proceeds from Sale of Property, Plant, and Equipment	$ 0.9
Sale of Property, Plant, and Equipment, Closing Costs	0.1
Gain (Loss) on Disposition of Property Plant Equipment	$ 0.1

Note 12 - Segment and Enterprise-wide Disclosures - Net Sales to Unaffiliated Customers by Geography (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Net sales	$ 48,883	$ 47,411	$ 50,115	$ 47,075	$ 40,954	$ 39,028	$ 42,108	$ 39,561	$ 193,484	$ 161,651	$ 154,424
Net sales	$ 48,883	$ 47,411	$ 50,115	$ 47,075	$ 40,954	$ 39,028	$ 42,108	$ 39,561	193,484	161,651	154,424
UNITED STATES
Net sales									117,811	99,463	93,866
Net sales									117,811	99,463	93,866
GERMANY
Net sales									13,420	11,223	12,968
Net sales									13,420	11,223	12,968
CANADA
Net sales									10,786	8,336	7,054
Net sales									10,786	8,336	7,054
UNITED KINGDOM
Net sales									8,561	5,841	5,046
Net sales									8,561	5,841	5,046
Other Countries [Member]
Net sales									42,906	36,788	35,490
Net sales									$ 42,906	$ 36,788	$ 35,490

Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-42

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-40

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-41

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-4

Note 8 - Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2023

Lease, Cost [Table Text Block]

	Location (leases)	Purpose	Approx. Sq. Ft.	Expiration

Americas
	Burlington, MA (4)	Corporate headquarters and manufacturing	96,476	December 2034
	North Brunswick, NJ (1)	Artegraft biologic business	16,732	October 2029
	Burlington, MA (1)	US distribution	12,878	December 2030
	Fox River Grove, IL (3)	RestoreFlow allografts business	11,765	November 2025
	Vaughn, Canada	Canada sales office and distribution	3,192	February 2026
	Chandler, Arizona	US sales office	2,058	August 2025

Europe, Middle East and Africa
	Sulzbach, Germany	European headquarters and distribution	21,410	June 2031
	Milan,Italy	Italy sales office and distribution	5,705	July 2027
	Hereford, England	United Kingdom sales office and distribution	3,575	October 2029
	Madrid, Spain	Spain sales office	2,260	June 2029

Asia Pacific
	Singapore	Asia Pacific headquarters and distribution	1,270	June 2024
	Tokyo, Japan	Japan sales office and distribution	4,236	July 2025
	Bangkok, Thailand	Thailand sales office and distribution	2,810	August 2026
	Seoul, Korea	Korea sales office and distribution	2,300	April 2027
	Shanghai, China	China sales office and distribution	1,152	August 2024
	Ballarat, Australia	Supply facility	Up to 350 acres	December 2030

	Year ended			Year ended
	December 31,			December 31,
	2023			2022
	(in thousands)			(in thousands)

Lease cost
Operating lease cost	$	2,420		$	2,203
Short-term lease cost		378			632
Total lease cost	$	2,798		$	2,835

Other information
Cash paid for amounts included in the measurement of operating lease liabilities	$	3,139		$	2,878

Right-of-use assets obtained in exchange for new operating lease liabilities	$	4,813		$	2,766


Weighted average remaining lease term - operating leases (in years)		7.3			7.1

Weighted average discount rate - operating leases		6.57	%		4.93	%

Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]

Year ending December 31,
2024	$	3,622
2025		3,364
2026		2,699
2027		2,503
2028		2,469
Thereafter		10,906
Adjustment to net present value as of December 31, 2023		(6,468	)

Minimum noncancelable lease liability	$	19,095

Note 1 - Significant Accounting Policies and Related Matters - Summary of Advertising Costs (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Advertising expense	$ 240	$ 195	$ 236

Note 3 - Inventory and Other Deferred Costs - Summary of Inventories and Other Deferred Costs (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Raw materials	$ 18,333	$ 14,929
Work-in-process	2,869	3,662
Finished products	31,131	26,688
Other deferred costs	5,747	4,992
Total inventory and other deferred costs	$ 58,080	$ 50,271

Note 13 - Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2023

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

	Year ended December 31,
	2023			2022			2021
	(in thousands)
Beginning balance	$	1,339		$	1,492		$	2,240
Additions		-			-			-
Payments		-			-			-
Change in fair value included in earnings		(115	)		(153	)		(748	)

Ending balance	$	1,224		$	1,339		$	1,492

Note 4 - Property and Equipment - Summary of Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Gross property and equipment	$ 43,242	$ 43,025
Less accumulated depreciation	(21,488)	(25,124)
Property and equipment, net	21,754	17,901
Computers and Equipment [Member]
Gross property and equipment	5,319	5,689
Machinery and Equipment [Member]
Gross property and equipment	16,942	22,104
Building and Leasehold Improvements [Member]
Gross property and equipment	$ 20,981	$ 15,232

Note 8 - Commitments and Contingencies - Additional Lease information (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($) ft²	Dec. 31, 2022 USD ($)
Lease cost
Operating lease cost \| $	$ 2,420	$ 2,203
Short-term lease cost \| $	378	632
Total lease cost \| $	2,798	2,835
Cash paid for amounts included in the measurement of operating lease liabilities \| $	3,139	2,878
Right-of-use assets obtained in exchange for new operating lease liabilities \| $	$ 4,813	$ 2,766
Weighted average remaining lease term - operating leases (in years) (Year)	7 years 3 months 18 days	7 years 1 month 6 days
Weighted average discount rate - operating leases	6.57%	4.93%
Principal Worldwide Executive, Distribution, and Manufacturing Operations Facilities [Member] \| Americas [Member]
Area of Real Estate Property	96,476
Lease cost
Area of Real Estate Property	96,476
North Brunswick, New Jersey [Member] \| Americas [Member]
Area of Real Estate Property	16,732
Lease cost
Area of Real Estate Property	16,732
Burlington Massachusetts [Member] \| Americas [Member]
Area of Real Estate Property	12,878
Lease cost
Area of Real Estate Property	12,878
Fox River Grove, Illinois [Member] \| Americas [Member]
Area of Real Estate Property	11,765
Lease cost
Area of Real Estate Property	11,765
Vaughn, Canada Lease [Member] \| Americas [Member]
Area of Real Estate Property	3,192
Lease cost
Area of Real Estate Property	3,192
Chandler, Arizona Lease [Member] \| Americas [Member]
Area of Real Estate Property	2,058
Lease cost
Area of Real Estate Property	2,058
International Operations Headquarter Facility [Member] \| EMEA [Member]
Area of Real Estate Property	21,410
Lease cost
Area of Real Estate Property	21,410
International Operations Headquarter Facility [Member] \| Asia Pacific [Member]
Area of Real Estate Property	1,270
Lease cost
Area of Real Estate Property	1,270
Milan, Italy Lease [Member] \| EMEA [Member]
Area of Real Estate Property	5,705
Lease cost
Area of Real Estate Property	5,705
Hereford, England [Member] \| EMEA [Member]
Area of Real Estate Property	3,575
Lease cost
Area of Real Estate Property	3,575
Madrid, Spain Lease [Member] \| EMEA [Member]
Area of Real Estate Property	2,260
Lease cost
Area of Real Estate Property	2,260
Tokyo, Japan Lease [Member] \| Asia Pacific [Member]
Area of Real Estate Property	4,236
Lease cost
Area of Real Estate Property	4,236
Bangkok, Thailand Lease [Member] \| Asia Pacific [Member]
Area of Real Estate Property	2,810
Lease cost
Area of Real Estate Property	2,810
Seoul, Korea Lease [Member] \| Asia Pacific [Member]
Area of Real Estate Property	2,300
Lease cost
Area of Real Estate Property	2,300
Shanghai, China Lease [Member] \| Asia Pacific [Member]
Area of Real Estate Property	1,152
Lease cost
Area of Real Estate Property	1,152
Victoria, Australia Lease [Member] \| Asia Pacific [Member]
Area of Real Estate Property	350
Lease cost
Area of Real Estate Property	350

Note 9 - Income Taxes

12 Months Ended

Dec. 31, 2023

Income Tax Disclosure [Text Block]

9. Income Taxes

Income (loss) before income taxes is as follows:

	Year ended December 31,
	2023		2022		2021
	(in thousands)

United States	$	37,356	$	26,274	$	34,153
Foreign		2,119		1,216		134

Total	$	39,475	$	27,490	$	34,287

Certain of our foreign subsidiaries are included in the U.S. tax return as branches but are included as foreign for purposes of the table above.

The provision (benefit) for income taxes is as follows:

	Year ended December 31,
	2023		2022			2021
			(in thousands)
Current:
Federal	$	6,203	$	5,063		$	5,024
State		1,300		938			990
Foreign		1,084		1,035			1,287

		8,587		7,036			7,301
Deferred:
Federal		616		(144	)		63
State		122		(83	)		(9	)
Foreign		45		45			25

		783		(182	)		79

Provision for income taxes	$	9,370	$	6,854		$	7,380

We have reviewed the tax positions taken, or to be taken, in our tax returns for all tax years currently open to examination by a taxing authority. As of December 31, 2023, the gross amount of unrecognized tax benefits exclusive of interest and penalties was $0.6 million, which may increase within the twelve months ending December 31, 2024. We remain subject to examination until the statute of limitations expires for each remaining respective tax jurisdiction. The statute of limitations will be open with respect to these tax positions through 2030. A reconciliation of the beginning and ending amount of our unrecognized tax benefits is as follows:

	2023			2022			2021
	(in thousands)
Unrecognized tax benefits at the beginning of year	$	612		$	768		$	820
Additions/adjustments for tax positions of current year		-			-			-
Additions/adjustments for tax positions of prior years		(25	)		(57	)		(52	)
Reductions for settlements with taxing authorities		-			-			-
Reductions for lapses of the applicable statutes of limitations		-			(99	)		-
Unrecognized tax benefits at the end of the year	$	587		$	612		$	768

Deferred taxes are attributable to the following temporary differences:

	As of December 31,
	2023			2022
	(in thousands)
Deferred tax assets:
Inventory	$	2,280		$	2,002
Net operating loss carryforwards		942			1,027
Tax credit carryforwards		1,092			996
Capital loss carryforwards		462			462
Reserves and accruals		823			1,090
Operating lease liabilities		3,721			3,295
Intangible assets		4,503			4,468
Stock options		696			446
Other		1,741			573

Total deferred tax assets		16,260			14,359

Deferred tax liabilities:
Property and equipment		(2,996	)		(1,473	)
Goodwill		(6,311	)		(5,610	)
Operating lease right-of-use assets		(3,472	)		(3,066	)
Foreign branch deferred offset		(700	)		(742	)
Other		(183	)		(164	)

Total deferred tax liabilities		(13,662	)		(11,055	)

Net deferred tax assets before valuation allowance		2,598			3,304

Valuation allowance		(1,702	)		(1,628	)

Net deferred tax liabiltity	$	896		$	1,676

Deferred tax classification
Long-term deferred tax asset	$	1,003		$	1,745
Long-term deferred tax liability		(107	)		(69	)

Net long-term deferred tax asset	$	896		$	1,676

In 2022, we decreased our valuation allowance by $0.1 million mainly attributable to Australian net operating loss carry forwards and Massachusetts credit carryforwards. In 2023, we increased our valuation allowance by $0.1 million mainly attributable to Australian net operating loss carry forwards and Massachusetts credit carryforwards.

As of December 31, 2023, we have provided a valuation allowance of $1.7 million for deferred tax assets primarily related to Australian net operating loss and capital loss carry forwards and Massachusetts tax credit carry forwards that are not expected to be realized. The valuation allowance against our deferred tax assets may require adjustment in the future based on changes in the mix of temporary differences, changes in tax laws, and operating performance.

Realization of our deferred tax assets is dependent on our generating sufficient taxable income in future periods. Although we believe it is more likely than not that future taxable income will be sufficient to allow us to recover substantially all of the value of our deferred tax assets remaining after we apply the valuation allowances, realization is not assured and future events could cause us to change our judgment. In the event that actual results differ from our estimates, or we adjust these estimates in the future periods, further adjustments to our valuation allowance may be recorded, which could materially impact our financial position and net income (loss) in the period of the adjustment.

As of December 31, 2023, we have net operating loss carryforwards in Australia of $1.2 million that do not expire, in France of $1.7 million that do not expire, in Spain of $0.5 million that do not expire, in Norway of $0.1 million that do not expire, and in China of $0.4 million that expire in four years. We have a capital loss carryforward in Australia of $1.5 million that does not expire. We also have state tax credit carryforwards of approximately $1.7 million that are available to reduce future tax liabilities, which begin to expire in 2030, or can be carried forward indefinitely.

In December 2018, we reevaluated our international operations and as a result, are no longer indefinitely reinvested with respect to undistributed earnings from our German and Australian subsidiaries. There was no material deferred tax expense recorded for foreign and state tax costs associated with the future remittance of these undistributed earnings. We remain permanently reinvested with respect to undistributed earnings from our other foreign subsidiaries. It is not practicable to estimate the amount of deferred tax liability, if any, with respect to these permanently reinvested undistributed earnings.

A reconciliation of the U.S. federal statutory rate to our effective tax rate is as follows:

	2023			2022			2021

Federal statutory rate		21.0	%		21.0	%		21.0	%
State tax, net of federal benefit		2.8	%		2.7	%		2.7	%
Effect of foreign taxes		1.7	%		4.0	%		3.7	%
Federal tax on foreign income		0.3	%		0.0	%		0.2	%
Valuation allowance		0.2	%		(0.2	%)		(0.1	%)
Foreign deferred tax liability offset		(0.1	%)		(0.2	%)		(0.1	%)
Research & development tax credits		(0.6	%)		0.0	%		(0.4	%)
Stock options		(1.8	%)		0.0	%		(3.1	%)
Uncertain tax positions		0.1	%		(0.3	%)		0.2	%
Other permanent differences		0.4	%		(1.8	%)		(2.4	%)
Other		(0.3	%)		(0.3	%)		(0.2	%)

Effective tax rate		23.7	%		24.9	%		21.5	%

We are not currently under income tax audit in any tax jurisdictions.

As of December 31, 2023, a summary of the tax years that remain subject to examination in our most significant tax jurisdictions are:

United States	2020 and forward
Foreign	2016 and forward

Supplemental disclosures of cash flow information are as follows:

	Year ended December 31,
	2023		2022		2021
	(in thousands)
Cash paid for income taxes, net	$	7,549	$	8,343	$	10,147

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//740/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-21

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482526/740-270-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-17

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482603/740-30-50-2

Note 9 - Income Taxes (Tables)

12 Months Ended

Dec. 31, 2023

Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]

	Year ended December 31,
	2023		2022		2021
	(in thousands)

United States	$	37,356	$	26,274	$	34,153
Foreign		2,119		1,216		134

Total	$	39,475	$	27,490	$	34,287

Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]

	Year ended December 31,
	2023		2022			2021
			(in thousands)
Current:
Federal	$	6,203	$	5,063		$	5,024
State		1,300		938			990
Foreign		1,084		1,035			1,287

		8,587		7,036			7,301
Deferred:
Federal		616		(144	)		63
State		122		(83	)		(9	)
Foreign		45		45			25

		783		(182	)		79

Provision for income taxes	$	9,370	$	6,854		$	7,380

Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]

	2023			2022			2021
	(in thousands)
Unrecognized tax benefits at the beginning of year	$	612		$	768		$	820
Additions/adjustments for tax positions of current year		-			-			-
Additions/adjustments for tax positions of prior years		(25	)		(57	)		(52	)
Reductions for settlements with taxing authorities		-			-			-
Reductions for lapses of the applicable statutes of limitations		-			(99	)		-
Unrecognized tax benefits at the end of the year	$	587		$	612		$	768

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]

	As of December 31,
	2023			2022
	(in thousands)
Deferred tax assets:
Inventory	$	2,280		$	2,002
Net operating loss carryforwards		942			1,027
Tax credit carryforwards		1,092			996
Capital loss carryforwards		462			462
Reserves and accruals		823			1,090
Operating lease liabilities		3,721			3,295
Intangible assets		4,503			4,468
Stock options		696			446
Other		1,741			573

Total deferred tax assets		16,260			14,359

Deferred tax liabilities:
Property and equipment		(2,996	)		(1,473	)
Goodwill		(6,311	)		(5,610	)
Operating lease right-of-use assets		(3,472	)		(3,066	)
Foreign branch deferred offset		(700	)		(742	)
Other		(183	)		(164	)

Total deferred tax liabilities		(13,662	)		(11,055	)

Net deferred tax assets before valuation allowance		2,598			3,304

Valuation allowance		(1,702	)		(1,628	)

Net deferred tax liabiltity	$	896		$	1,676

Deferred tax classification
Long-term deferred tax asset	$	1,003		$	1,745
Long-term deferred tax liability		(107	)		(69	)

Net long-term deferred tax asset	$	896		$	1,676

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]

	2023			2022			2021

Federal statutory rate		21.0	%		21.0	%		21.0	%
State tax, net of federal benefit		2.8	%		2.7	%		2.7	%
Effect of foreign taxes		1.7	%		4.0	%		3.7	%
Federal tax on foreign income		0.3	%		0.0	%		0.2	%
Valuation allowance		0.2	%		(0.2	%)		(0.1	%)
Foreign deferred tax liability offset		(0.1	%)		(0.2	%)		(0.1	%)
Research & development tax credits		(0.6	%)		0.0	%		(0.4	%)
Stock options		(1.8	%)		0.0	%		(3.1	%)
Uncertain tax positions		0.1	%		(0.3	%)		0.2	%
Other permanent differences		0.4	%		(1.8	%)		(2.4	%)
Other		(0.3	%)		(0.3	%)		(0.2	%)

Effective tax rate		23.7	%		24.9	%		21.5	%

Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]

	Year ended December 31,
	2023		2022		2021
	(in thousands)
Cash paid for income taxes, net	$	7,549	$	8,343	$	10,147

Note 7 - Accrued Expenses and Other Long-term Liabilities - Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Compensation and related taxes	$ 13,353	$ 10,770
Accrued expenses	5,152	3,748
Accrued purchases	4,251	4,640
Income and other taxes	390	449
Professional fees	104	108
Other	400	252
Total	$ 23,650	$ 19,967

Note 13 - Fair Value Measurements (Details Textual) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022	Sep. 30, 2021	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2019	Oct. 11, 2019
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability				$ (78)	$ (108)	$ (674)
Artegraft Inc [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High				17,500
Business Combination, Contingent Consideration, Liability				400
CardioCel and VascuCel Biologic Patches [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High							$ 7,800
CardioCel and VascuCel Biologic Patches [Member] \| Fair Value, Inputs, Level 3 [Member]
Business Combination, Contingent Consideration, Liability								$ 2,300
CardioCel and VascuCel Biologic Patches [Member] \| Third Holdback [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	$ 2,000						2,000
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	$ 100	$ (100)	$ (500)	$ 100
CardioCel and VascuCel Biologic Patches [Member] \| Audited Carve-Out Financial Statements of the Acquired Business [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High							300
CardioCel and VascuCel Biologic Patches [Member] \| Extension of Product Shelf Life from 36 Months to 60 Months in the First Anniversary of Closing Date [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High							500
CardioCel and VascuCel Biologic Patches [Member] \| Achievement of Specified Levels of Revenues [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High							$ 5,000

Note 6 - Revolving Line of Credit and Long-term Debt

12 Months Ended

Dec. 31, 2023

Debt Disclosure [Text Block]

6. Revolving Line of Credit and Long-term Debt

In connection with the acquisition of the Artegraft biologic graft business, we incurred debt in the amount of $65 million under a senior secured credit facility with a group of banks. This credit arrangement included a $25 million revolving credit line that was fully drawn at inception, as well as a $40 million five-year term loan. During the year ended December 31, 2020, we made scheduled principal payments on the term loan of $1.0 million and repaid the revolving line of credit in full. During the year ended December 31, 2021, we made scheduled principal payments on the term loan of $1.0 million, repaid the loan in full, and terminated the credit agreement in accordance with its terms.

Under the terms of the agreement, the loans bore interest at a rate per annum of, at our option, either (i) the Base Rate plus an applicable margin of from 1.25% to 1.75% depending on our consolidated leverage ratio, or (ii) the Eurodollar Rate plus an applicable margin of from 2.25% to 2.75% depending on our consolidated leverage ratio. Base Rate was defined in the credit agreement as a fluctuating rate per annum of the Federal Funds rate plus 0.5% or the prime rate of interest established from time to time by KeyBank National Association. Cash paid for interest during both of the years ended December 31, 2021 and 2020 was $0.9 million.

We incurred debt issuance costs in connection with this credit arrangement of approximately $1.8 million. These costs were allocated between the revolving line of credit and the term loans, with the portion related to the revolving line of credit of $0.7 million recorded in other assets on our balance sheet, and the portion allocated to the term loan recorded as a deduction from the amount of the debt. All of these transaction costs were being amortized into interest expense on a straight-line basis as the result would not be materially different from using the interest method, over the five-year term of the arrangement. This resulted in an effective interest rate of approximately 4.2%.

In November 2021, we terminated the credit agreement, including the revolving line of credit, as permitted under the original agreement.

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//470/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Note 10 - Stockholders' Equity - Summary of Repurchases (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Shares of common stock repurchased for net settlement of equity awards (in shares)	15,917	13,690	16,333
Restricted Stock Units (RSUs) [Member]
Average per share repurchase price (in dollars per share)	$ 53.59	$ 46.9	$ 49.1
Aggregate purchase price (in thousands)	$ 853	$ 642	$ 802

Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.

Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.

Note 1 - Significant Accounting Policies and Related Matters (Tables)

12 Months Ended

Dec. 31, 2023

Disaggregation of Revenue [Table Text Block]

	Year ended December 31,
	2023		2022		2021
Americas	$	130,308	$	109,439	$	102,265
Europe, Middle East and Africa		51,099		41,854		42,132
Asia Pacific		12,077		10,358		10,027
Total	$	193,484	$	161,651	$	154,424

Schedule of Advertising Expenses [Table Text Block]

	Year ended December 31,
	2023		2022		2021
			(in thousands)

Advertising expense	$	240	$	195	$	236

Financing Receivable, Allowance for Credit Loss [Table Text Block]

	Balance at		Additions		Deductions		Balance at
	Beginning		(recoveries) charged		from		End of
	of Period		to Income		Reserves		Period
	(in thousands)
Allowance for credit losses and sales returns:
Year ended December 31, 2023	$	835	$	344	$	238	$	941
Year ended December 31, 2022		679		637		481		835
Year ended December 31, 2021		623		263		207		679

Schedule of Property, Plant and Equipment Estimated Useful Lives [Table Text Block]

Description	Useful Life (in years)
Computer hardware	3	–	5
Machinery and equipment	3	–	10
Building and leasehold improvements	The shorter of its useful life or lease term

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

		Year ended December 31,
	2023		2022		2021
		(in thousands, except per share data)
Basic:
Net income available for common stockholders	$	30,105	$	20,636	$	26,907

Weighted average shares outstanding		22,217		21,975		21,157

Basic earnings per share	$	1.36	$	0.94	$	1.27

Diluted:
Net income available for common stockholders	$	30,105	$	20,636	$	26,907

Weighted-average shares outstanding		22,217		21,975		21,157
Common stock equivalents, if dilutive		206		196		318

Shares used in computing diluted earnings per common share		22,423		22,171		21,475

Diluted earnings per share	$	1.34	$	0.93	$	1.25

Shares excluded in computing diluted earnings per share as those shares would be anti-dilutive		295		293		10

Note 8 - Commitments and Contingencies (Details Textual) $ in Millions	Dec. 31, 2022 USD ($)
Purchase Obligation	$ 5.1

Note 1 - Significant Accounting Policies and Related Matters (Details Textual) $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Number of Operating Segments	1	1
Accounts Receivable, after Allowance for Credit Loss, Current	$ 25,064	$ 22,040
Marketable Security, Unrealized Gain (Loss)	1,200	1,800
Capitalized Computer Software, Net	3,600
Goodwill, Impairment Loss	0	0	$ 0
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	0	0	$ 0
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax	3,400	4,200
AOCI, Debt Securities, Available-for-Sale, Adjustment, after Tax	1,200	$ 1,800
ITALY
Accounts Receivable, after Allowance for Credit Loss, Current	1,100
SPAIN
Accounts Receivable, after Allowance for Credit Loss, Current	1,000
FRANCE
Accounts Receivable, after Allowance for Credit Loss, Current	1,200
Geographic Distribution, Foreign [Member]
Cash, Ending Balance	$ 10,000
Minimum [Member]
Period of Payments Received from Customers (Day)	30 days
Finite-Lived Intangible Asset, Useful Life	2 years
Minimum [Member] \| Computers and Equipment [Member]
Property, Plant and Equipment, Useful Life	3 years
Minimum [Member] \| Machinery and Equipment [Member]
Property, Plant and Equipment, Useful Life	3 years
Maximum [Member]
Period of Payments Received from Customers (Day)	60 days
Finite-Lived Intangible Asset, Useful Life	16 years
Maximum [Member] \| Computers and Equipment [Member]
Property, Plant and Equipment, Useful Life	5 years
Maximum [Member] \| Machinery and Equipment [Member]
Property, Plant and Equipment, Useful Life	10 years

Note 3 - Inventory and Other Deferred Costs (Details Textual) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Other Inventory, Materials, Supplies and Merchandise under Consignment, Gross	$ 2.0	$ 1.5

Note 1 - Significant Accounting Policies and Related Matters - Disaggregation of Revenue by Major Geographic Area (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Americas	$ 193,484	$ 161,651	$ 154,424
Americas [Member]
Americas	130,308	109,439	102,265
EMEA [Member]
Americas	51,099	41,854	42,132
Asia Pacific [Member]
Americas	$ 12,077	$ 10,358	$ 10,027

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

Note 10 - Stockholders' Equity - Stock-based Compensation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Stock-based compensation	$ 5,319	$ 4,173	$ 3,479
Cost of Sales [Member]
Stock-based compensation	686	494	407
Sales [Member]
Stock-based compensation	966	771	527
General and Administrative Expense [Member]
Stock-based compensation	3,143	2,500	2,185
Research and Development Expense [Member]
Stock-based compensation	524	408	360
Share-Based Payment Arrangement, Option [Member]
Stock-based compensation	2,705	2,487	2,199
Restricted Stock Units (RSUs) [Member]
Stock-based compensation	1,951	1,654	1,247
Performance Shares [Member]
Stock-based compensation	$ 663	$ 32	$ 33

Note 15 - Quarterly Financial Data (Unaudited) - Quarterly Financial Data (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Net sales	$ 48,883	$ 47,411	$ 50,115	$ 47,075	$ 40,954	$ 39,028	$ 42,108	$ 39,561	$ 193,484	$ 161,651	$ 154,424
Gross profit	33,265	30,815	32,086	30,883	26,054	25,070	27,810	25,962	127,049	104,896	101,382
Income from operations	10,206	9,180	9,452	7,874	6,967	6,150	5,784	7,928	36,712	26,829	36,425
Net income	$ 8,465	$ 7,502	$ 8,098	$ 6,040	$ 5,627	$ 5,456	$ 3,515	$ 6,038	$ 30,105	$ 20,636	$ 26,907
Earnings per share
Earnings per share of common stock: (in dollars per share)	$ 0.38	$ 0.34	$ 0.36	$ 0.27	$ 0.26	$ 0.25	$ 0.16	$ 0.28	$ 1.36	$ 0.94	$ 1.27
Diluted (in dollars per share)	$ 0.38	$ 0.33	$ 0.36	$ 0.27	$ 0.25	$ 0.25	$ 0.16	$ 0.27	$ 1.34	$ 0.93	$ 1.25

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-15

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-7

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482662/260-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-10

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-52

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-7

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-15

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-7

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482662/260-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-52

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-7

Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

Note 9 - Income Taxes - Deferred Taxes (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Inventory	$ 2,280	$ 2,002
Net operating loss carryforwards	942	1,027
Tax credit carryforwards	1,092	996
Capital loss carryforwards	462	462
Reserves and accruals	823	1,090
Operating lease liabilities	3,721	3,295
Intangible assets	4,503	4,468
Stock options	696	446
Other	1,741	573
Total deferred tax assets	16,260	14,359
Property and equipment	(2,996)	(1,473)
Goodwill	(6,311)	(5,610)
Operating lease right-of-use assets	(3,472)	(3,066)
Foreign branch deferred offset	(700)	(742)
Other	(183)	(164)
Total deferred tax liabilities	(13,662)	(11,055)
Net deferred tax assets before valuation allowance	2,598	3,304
Valuation allowance	(1,702)	(1,628)
Net deferred tax liabiltity	896	1,676
Deferred tax assets	1,003	1,745
Long-term deferred tax liability	(107)	(69)
Net long-term deferred tax asset	$ 896	$ 1,676

Note 4 - Property and Equipment

12 Months Ended

Dec. 31, 2023

Property, Plant and Equipment Disclosure [Text Block]

4. Property and Equipment

Property and equipment consists of the following:

	As of December 31,
	2023			2022
	(in thousands)
Computer hardware	$	5,319		$	5,689
Machinery and equipment		16,942			22,104
Building and leasehold improvements		20,981			15,232

Gross property and equipment		43,242			43,025
Less accumulated depreciation		(21,488	)		(25,124	)

Property and equipment, net	$	21,754		$	17,901

During the years ended December 31, 2023, 2022 and 2021 we wrote off fully depreciated assets with gross values of $7.1 million, $0.5 million and $0.1 million, respectively.

Depreciation expense is as follows:

	Year ended December 31,
	2023		2022		2021
			(in thousands)

Depreciation expense	$	3,423	$	3,250	$	3,280

Note 12 - Segment and Enterprise-wide Disclosures

12 Months Ended

Dec. 31, 2023

Segment Reporting Disclosure [Text Block]

12. Segment and Enterprise-wide Disclosures

The FASB establishes standards for reporting information regarding operating segments in financial statements. Operating segments are identified as components of an enterprise that engage in business activities for which separate, discrete financial information is available and is regularly reviewed by the chief operating decision-maker in making decisions on how to allocate resources and assess performance. We view our operations and manage our business as one operating segment. No discrete operating information is prepared by us except for sales by product line and operations by legal entity for local purposes.

Most of our revenues are generated in the United States, Germany, the UK and other European countries and Canada. Substantially all of our assets are located in the United States and Germany. Net sales to unaffiliated customers by country were as follows:

	Year ended December 31,
	2023		2022		2021
	(in thousands)

United States	$	117,811	$	99,463	$	93,866
Germany		13,420		11,223		12,968
Canada		10,786		8,336		7,054
United Kingdom		8,561		5,841		5,046
Other countries		42,906		36,788		35,490

Net sales	$	193,484	$	161,651	$	154,424

Long-term assets by country, including property and equipment, net and right-of-use leased assets were as follows:

	As of December 31,
	2023		2022
	(in thousands)

United States	$	34,729	$	29,042
Germany		2,350		2,462
Other countries		2,702		2,031

Total long-term assets	$	39,781	$	33,535

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-15

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-42

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-40

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//280/tableOfContent

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-26

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-34

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-41

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-21

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-21

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Note 14 - Accumulated Other Comprehensive Income (Loss)

12 Months Ended

Dec. 31, 2023

Comprehensive Income (Loss) Note [Text Block]

14. Accumulated Other Comprehensive Income (Loss)

	Year ended December 31,
	2023			2022			2021
	(in thousands)
Beginning balance	$	(6,031	)	$	(3,435	)	$	(1,525	)

Other comprehensive income (loss) before reclassifications		1,406			(2,596	)		(1,910	)
Amounts reclassified from accumulated other comprehensive loss		-			-			-

Ending Balance	$	(4,625	)	$	(6,031	)	$	(3,435	)

Changes to our accumulated other comprehensive loss consisted primarily of foreign currency translation and unrealized losses on short-term marketable securities for the years ended December 31, 2023, 2022 and 2021.

Note 10 - Stockholders' Equity - Summary of RSU Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Granted (in shares)	26,883
Granted, weighted average grant date fair value (in dollars per share)	$ 54.65
Vested (in shares)	0
Vested (in dollars per share)	$ 0
Canceled (in shares)	(1,192)
Canceled (in dollars per share)	$ 47.19
Outstanding (in shares)	54,164
Outstanding, weighted average grant date fair value (in dollars per share)	$ 50.85
Restricted Stock Units (RSUs) [Member]
Outstanding (in shares)	133,144	133,831	147,015
Outstanding, weighted average grant date fair value (in dollars per share)	$ 42.38	$ 38.26	$ 30.24
Granted (in shares)	48,225	51,031	48,298
Granted, weighted average grant date fair value (in dollars per share)	$ 54.68	$ 47.11	$ 48.65
Vested (in shares)	(49,400)	(45,489)	(51,414)
Vested (in dollars per share)	$ 39.31	$ 35.75	$ 26.32
Canceled (in shares)	(5,975)	(6,229)	(10,068)
Canceled (in dollars per share)	$ 42.89	$ 40.79	$ 30.7
Outstanding (in shares)	125,994	133,144	133,831
Outstanding, weighted average grant date fair value (in dollars per share)	$ 48.2	$ 42.38	$ 38.26

Note 12 - Segment and Enterprise-wide Disclosures (Details Textual)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Number of Operating Segments	1	1

Note 1 - Significant Accounting Policies and Related Matters - Computation of Basic and Diluted Net Income Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Net income	$ 8,465	$ 7,502	$ 8,098	$ 6,040	$ 5,627	$ 5,456	$ 3,515	$ 6,038	$ 30,105	$ 20,636	$ 26,907
Weighted-average shares outstanding: (in shares)									22,217	21,975	21,157
Earnings per share of common stock: (in dollars per share)	$ 0.38	$ 0.34	$ 0.36	$ 0.27	$ 0.26	$ 0.25	$ 0.16	$ 0.28	$ 1.36	$ 0.94	$ 1.27
Common stock equivalents, if dilutive (in shares)									206	196	318
Diluted (in shares)									22,423	22,171	21,475
Diluted (in dollars per share)	$ 0.38	$ 0.33	$ 0.36	$ 0.27	$ 0.25	$ 0.25	$ 0.16	$ 0.27	$ 1.34	$ 0.93	$ 1.25
Shares excluded in computing diluted earnings per share as those shares would be anti-dilutive (in shares)									295	293	10

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-15

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-7

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482662/260-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-52

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-7

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

Note 2 - Divestures

12 Months Ended

Dec. 31, 2023

Restructuring and Related Activities Disclosure [Text Block]

2. Divestitures

On April 26, 2022, we committed to a plan to close our St. Etienne, France factory, which supported our LeMaitre Cardial SAS (Cardial) business, in order to streamline manufacturing operations and reduce expenses. The Cardial business consisted of the manufacture of polyester vascular grafts, valvulotomes, surgical glue and selected OEM devices. We acquired the Cardial business in 2018.

On June 30, 2022, we ceased operations at the St. Etienne, France factory. The closure resulted in a restructuring charge of $3.1 million for the year ended December 31, 2022. Charges primarily consisted of employment termination costs, impairment of fixed assets and inventory, and third-party costs.

On October 10, 2022 we sold the St. Etienne, France building, building improvements, and land for $0.9 million less closing costs of $0.1 million, resulting in a gain of approximately $0.1 million recorded for the year ended December 31, 2022.

For the year ended December 31, 2023, we recorded additional restructuring charges of $0.5 million in conjunction with the St. Etienne, France factory closure. The additional charges consisted primarily of employment termination, settlement, legal and other third-party costs.

Note 5 - Goodwill and Other Intangibles - Components of Identifiable Intangible Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Gross carrying value	$ 72,130	$ 70,854
Accumulated amortization	30,419	24,327
Net carrying value	41,711	46,527
Product Technology and Intellectual Property [Member]
Gross carrying value	29,549	29,549
Accumulated amortization	16,048	13,319
Net carrying value	13,501	16,230
Trademarks, Tradenames and Licenses [Member]
Gross carrying value	3,767	3,647
Accumulated amortization	1,909	1,533
Net carrying value	1,858	2,114
Customer Relationships [Member]
Gross carrying value	37,171	36,197
Accumulated amortization	11,064	8,359
Net carrying value	26,107	27,838
Other Intangible Assets [Member]
Gross carrying value	1,643	1,461
Accumulated amortization	1,398	1,116
Net carrying value	$ 245	$ 345

Note 12 - Segment and Enterprise-wide Disclosures (Tables)

12 Months Ended

Dec. 31, 2023

Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]

	Year ended December 31,
	2023		2022		2021
	(in thousands)

United States	$	117,811	$	99,463	$	93,866
Germany		13,420		11,223		12,968
Canada		10,786		8,336		7,054
United Kingdom		8,561		5,841		5,046
Other countries		42,906		36,788		35,490

Net sales	$	193,484	$	161,651	$	154,424

Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]

	As of December 31,
	2023		2022
	(in thousands)

United States	$	34,729	$	29,042
Germany		2,350		2,462
Other countries		2,702		2,031

Total long-term assets	$	39,781	$	33,535

Note 9 - Commitments and Contingencies - Minimum Rental Commitments (Details) $ in Thousands	Dec. 31, 2023 USD ($)
2024	$ 3,622
2025	3,364
2026	2,699
2027	2,503
Lessee, Operating Lease, Liability, to be Paid, Year Five	2,469
Thereafter	10,906
Adjustment to net present value as of December 31, 2022	(6,468)
Minimum noncancelable lease liability	$ 19,095

Note 11 - Profit-sharing Plan

12 Months Ended

Dec. 31, 2023

Compensation and Employee Benefit Plans [Text Block]

11. Profit-Sharing Plan

We offer a 401(k) profit-sharing plan (the Plan) covering eligible U.S. employees to make tax-deferred contributions, a portion of which are matched by us. We may also make discretionary profit sharing contributions to the Plan in an amount determined by our Board of Directors. Our contributions vest ratably over six years of employment and amounted to approximately $0.8 million, $0.6 million and $0.5 million for 2023, 2022 and 2021, respectively. A similar plan is offered to our Canadian employees.

Note 10 - Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2023